BEFORE THE GOVERNANCE SUBCOMMITTEE OF THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: AS INDICATED ON THE AGENDA

DATE: DECEMBER 22, 2008 3: 30 P. M.

REPORTER: BETH C. DRAIN, CSR CSR. NO. 7152

BRS FILE NO.: 83364

INDEX

ITEM	DESCRI PTI ON	PAGE NO.
CALL TO ORDE	R	3
ROLL CALL		3
PERFORMANCE	N OF POLICY/PROCEDURE FOR EVALUATION FOR, CHAIR, AND PRESIDENT	5
	N OF AMENDMENTS TO CIRM ERNANCE OLCYH	25
CLOSED SESSI	ON (NOT REPORTED)	54
PUBLIC REPOR	RT	54

	BARRISTERS' REPORTING SERVICE
1	MONDAY, DECEMBER 22, 2008
2	3:30 P.M.
3	
4	CHAIRPERSON LANSING: WHY DON'T I JUST
5	START. WELCOME, EVERYONE, TO THIS MEETING OF THE
6	GOVERNANCE SUBCOMMITTEE. WE HAVE PARTICIPANTS IN
7	SIX LOCATIONS. CIRM IN SAN FRANCISCO?
8	MS. KING: WE'RE HERE.
9	CHAI RPERSON LANSI NG: UC DAVI S?
10	DR. POMEROY: HERE.
11	CHAIRPERSON LANSING: LANCELOT LANE IN
12	L. A. ?
13	DR. FONTANA: HERE WITH PUBLIC.
14	CHAI RPERSON LANSING: UC I RVI NE?
15	DR. STEWARD: HERE.
16	CHAI RPERSON LANSI NG: CONNECT?
17	MR. ROTH: HERE.
18	CHAI RPERSON LANSING: OKAY. OBVIOUSLY WE
19	ARE IN L.A. SO, MELISSA, WOULD YOU PLEASE CALL THE
20	ROLL.
21	MS. KING: BOB KLEIN.
22	MR. KLEIN: HERE.
23	MS. KING: SHERRY LANSING.
24	CHAI RPERSON LANSI NG: HERE.
25	MS. KING: PHIL PIZZO. CLAIRE POMEROY.
	3

i	
1	DR. POMEROY: HERE.
2	MS. KING: JEANNIE FONTANA FOR JOHN REED.
3	DR. FONTANA: HERE.
4	MS. KING: DUANE ROTH.
5	MR. ROTH: HERE.
6	MS. KING: JEFF SHEEHY.
7	MR. SHEEHY: HERE.
8	MS. KING: AND OSWALD STEWARD.
9	DR. STEWARD: HERE.
10	MS. KING: FOR THE RECORD, WE DO HAVE A
11	QUORUM.
12	CHAI RPERSON LANSI NG: AGAI N, I APOLOGI ZE.
13	I HAVE NO IDEA WHY THAT PHONE DOESN'T WORK SINCE
14	THIS ONE LOOKS LIKE A MUCH LESS VALUABLE PHONE.
15	WE'RE GOING TO AGENDA ITEM 3, WHICH IS
16	CONSIDERATION OF POLICY/PROCEDURE FOR THE
17	PERFORMANCE EVALUATION OF OUR CHAIR, VICE CHAIR, AND
18	PRESIDENT. I JUST WANT TO SAY ON A PERSONAL LEVEL
19	THAT WE'VE BEEN VERY FORTUNATE TO HAVE BOB KLEIN AS
20	OUR CHAIR. AND I THINK I'VE SAID THIS PUBLICLY, AND
21	I WANT TO SAY IT AGAIN, BOB. NONE OF US WOULD BE
22	HERE WITHOUT YOUR LEADERSHIP, AND WE'RE INCREDIBLY
23	GRATEFUL FOR THAT.
24	MR. KLEIN: THANK YOU VERY MUCH.
25	CHAIRPERSON LANSING: AND, OF COURSE, I AM
	4

1	ALSO GRATEFUL TO ALAN TROUNSON AS OUR PRESIDENT
2	WHO'S DOING AN EXTRAORDINARY JOB. AND, OF COURSE,
3	ED PENHOET AS OUR VICE CHAIR UNTIL RECENTLY.
4	IN ORDER TO PROVIDE FEEDBACK TO THEM
5	REGARDING THEIR PERFORMANCE, WE WOULD LIKE TO PUT A
6	FORMAL PROCESS INTO PLACE TO CONDUCT PERFORMANCE
7	EVALUATIONS ON THE CHAIR, VICE CHAIR, AND PRESIDENT.
8	AND SO I'D LIKE TO ASK DR. CLAIRE POMEROY, WHO HAS
9	BEEN LEADING US IN THIS EFFORT, TO OPEN THE
10	DISCUSSION WITH SOME THOUGHTS. DR. POMEROY.
11	DR. POMEROY: THANK YOU VERY MUCH. THIS
12	REALLY GROWS OUT OF A REQUEST FROM THE PEOPLE
13	CURRENTLY OCCUPYING THESE THREE POSITIONS TO HAVE A
14	PROCESS BY WHICH WE WOULD DEFINE THE EXPECTATIONS
15	AND GIVE THEM FEEDBACK. SO I WANTED TO GO THROUGH
16	EACH OF THE THREE POSITIONS THAT YOU MENTIONED AND
17	GIVE THE GROUP A VERY HIGH LEVEL IDEA OF WHAT WE
18	HAVE BEEN TALKING ABOUT.
19	FIRST, FOR THE ICOC CHAIR, WE WANTED TO
20	CLARIFY THAT THE CHAIR REPORTS TO THE ICOC, THAT THE
21	CHAIR SHOULD HAVE A LIST OF OBJECTIVES OR
22	DELIVERABLES PREPARED ANNUALLY, AND THAT AT THE END
23	OF EACH YEAR AND MORE OFTEN AS NEEDED THERE WOULD BE
24	A PERFORMANCE EVALUATION.
25	THE ANNUAL OBJECTIVES AND THE PERFORMANCE
	5
	5

1	EVALUATION WOULD BE THE RESPONSIBILITY OF THE ICOC
2	AS A WHOLE AS REPRESENTED BY THE CHAIR OF THE
3	GOVERNANCE SUBCOMMITTEE AFTER DISCUSSION AND
4	APPROVAL BY THE ICOC. SO THE CHAIR OF THE
5	GOVERNANCE SUBCOMMITTEE WOULD BE THE CONDUIT THROUGH
6	WHICH THE OBJECTIVES AND PERFORMANCE EVALUATION
7	WOULD BE DELIVERED, BUT IT WOULD BE A CONSENSUS
8	OPINION FROM THE ICOC AS A WHOLE.
9	SIMILARLY FOR THE VICE CHAIR, VICE CHAIR
10	WOULD REPORT, WE PROPOSE, TO THE ICOC. THERE WOULD
11	BE A SIMILAR PREPARATION OF ANNUAL OBJECTIVES AND A
12	PERFORMANCE EVALUATION PERFORMED BY THE ICOC, IN
13	THIS CASE, AGAIN, AS REPRESENTED BY THE CHAIR OF THE
14	GOVERNANCE SUBCOMMITTEE AFTER DISCUSSION AND
15	APPROVAL BY THE ICOC.
16	THEN FINALLY FOR THE PRESIDENT, THAT WE
17	ALSO WANTED TO SUGGEST THAT WE CLARIFY THAT THE
18	PRESIDENT ALSO REPORTS TO THE ICOC, AND THE
19	PREPARATION OF ANNUAL OBJECTIVES AND PERFORMANCE
20	EVALUATION WOULD BE, AGAIN, PERFORMED BY THE ICOC IN
21	THIS CASE AS REPRESENTED BY THE CHAIR OF THE ICOC
22	AFTER DISCUSSION AND APPROVAL BY THE ENTIRE BOARD.
23	SO THAT IS A VERY BASIC PROCESS WHICH WE
24	HAVE NOT BEEN FORMALLY FOLLOWING, BUT WE THINK WE'RE
25	NOW AT A POINT IN THE MATURITY OF THE ORGANIZATION
	4

6

1	THAT IT'S TIME TO FORMALIZE THIS. SO I'D LIKE TO
2	OPEN UP THE DISCUSSION OF THOSE RECOMMENDATIONS FOR
3	COMMENT FROM THE COMMITTEE MEMBERS.
4	MR. KLEIN: CLAIRE, THIS IS BOB KLEIN.
5	AND FIRST OF ALL, THANK YOU FOR THE THOUGHT YOU' VE
6	PUT INTO THIS. TWO OR THREE MONTHS AGO, WHEN I
7	RAISED THIS TOPIC, IN TERMS OF NEEDING TO HAVE THIS
8	PERFORMANCE PROCESS, I THANK YOU FOR MOVING DOWN
9	THAT DIRECTION.
10	BUT I WOULD LIKE TO SAY THAT ONE OF THE
11	STRENGTHS OF THIS BOARD IS ITS DIVERSITY. AND THE
12	DIVERSITY OF OPINION IS HEALTHY; AND WHETHER IT'S AS
13	TO THE PRESIDENT, WHICH YOU ARE SUGGESTING THAT I BE
14	THE CONDUIT FOR, OR THE CHAIR OF THE GOVERNANCE
15	COMMITTEE, WE'RE SUGGESTING SHERRY BE THE CONDUIT
16	FOR, I THINK IT'S IMPORTANT FOR ME AND FOR THE
17	PRESIDENT TO GET DIRECT RESPONSE FROM THE BOARD SO
18	THAT THERE'S GIVE-AND-TAKE AND EITHER OF US CAN
19	REALLY UNDERSTAND WHERE DIFFERENT CONSTITUENCIES ARE
20	COMING FROM AS TO THEIR SENSE OF WHETHER THEIR NEEDS
21	ARE BEING MET AND TO WHETHER THEIR PARTICULAR
22	VISIONS OR CRITICAL INPUT IS BEING MET.
23	IT'S HARD TO DRIVE A CONSENSUS VIEW WHEN
24	WE HAVE SUCH RICH DIVERSITY WITH TREMENDOUS
25	DIFFERENCES IN EXPERIENCE. SO THE ACADEMIC RESEARCH
	7
	1

1	MEMBERS HAVE SOMETHING SPECIFIC THEY CAN CONTRIBUTE.
2	THE DEANS OF THE MEDICAL SCHOOLS HAVE A VERY
3	SPECIFIC KIND OF CONTRIBUTION WHICH MAY COVER
4	SEVERAL AREAS, THE PATIENT ADVOCATES, THE INDUSTRY
5	REPRESENTATIVES. WHEN YOU GET THAT ABILITY OF
6	FORMAL TIME SETTING TO GET MULTIPLE CONSTITUENCIES,
7	BUT THEN YOU REALLY CAN UNDERSTAND WHERE YOU' RE
8	MEETING NEEDS AND WHERE YOU'RE NOT, WHERE THERE'S
9	NEW IDEAS. TO FORCE IT INTO CONSENSUS IS VERY
10	TOUGH. SHERRY HAS EXTRAORDINARY SKILLS. I WOULD
11	HOPE THAT I HAVE SOME OF THEM. BUT NEITHER OF US
12	FORCING IT INTO CONSENSUS, I THINK, DOESN'T GIVE US
13	THE INPUT FROM THE RICHNESS OF THE DIVERSE
14	COMPONENTS OF THIS BOARD.
15	CHAIRPERSON LANSING: TELL ME, BOB, I'M
16	NOT SURE THAT WE'RE SAYING SOMETHING DIFFERENT. SO
17	I'M A LITTLE CONFUSED. SO HOW WOULD YOU SUGGEST
18	THAT WE DO IT?
19	MR. KLEIN: SO THE PROCESS IS DEVELOPED
20	FOR THE REVIEW, BUT THE BOARD AS A WHOLE REVIEWS,
21	WHETHER IT'S ME OR THE PRESIDENT OR THE VICE CHAIR,
22	AND THEN THERE IS A MEETING WITH THE ENTIRE BOARD
23	WHERE INDIVIDUAL MEMBERS CAN PROVIDE INPUT TO US.
24	THERE COULD BE A GENERAL STATEMENT.
25	DR. POMEROY: BOB, THIS IS CLAIRE. I JUST
	8

1	I THINK I DIDN'T EXPRESS THE PROPOSAL VERY WELL
2	BECAUSE THAT IS EXACTLY WHAT WE THOUGHT WAS THAT,
3	FOR INSTANCE, FOR THE EVALUATION OF THE PRESIDENT,
4	SINCE YOU WOULD BE THE REPRESENTATIVE, I WOULD
5	EXPECT YOU TO LEAD A CONVERSATION IN CLOSED SESSION
6	WITH THE ENTIRE BOARD, GET ALL OF THE INPUT, AND
7	ATTEMPT TO GET, YOU KNOW, AN OVERALL RATING, BUT
8	THERE MIGHT BE, YOU KNOW, A RANGE OF OPINIONS. BUT
9	ONE PERSON, YOU FOR THE PRESIDENT, WOULD REPORT THAT
10	TO THE PRESIDENT.
11	SO WE DON'T WANT THE PRESIDENT OR THE
12	CHAIR OR THE VICE CHAIR TO BE HAVING TO MEET
13	INDIVIDUALLY WITH 29 PEOPLE TO GET THEIR PERFORMANCE
14	EVALUATION, BUT THE EXPECTATION IS THAT THE
15	REPRESENTATIVE GETS THE INFORMATION IN A CLOSED
16	SESSION FROM THE ENTIRE BOARD THAT'S INCORPORATED
17	BOTH INTO THE FORMULATION OF THE OBJECTIVES AND THE
18	EVALUATION OF HOW WELL THEY WERE ACHIEVED.
19	CHAIRPERSON LANSING: AGAIN, I FEEL
20	COMFORTABLE WITH THAT BECAUSE I THINK WHAT YOU WILL
21	FIND IS THAT, YOU KNOW, IF YOU HAVE THE PERSON THERE
22	THAT'S ASKING FOR THE EVALUATION, NO MATTER HOW
23	HONEST PEOPLE WANT TO BE, THEY'RE A LITTLE
24	UNCOMFORTABLE. BUT IF YOU'RE THE REPRESENTATIVE,
25	LET'S SAY FOR THE PRESIDENT AND DOING THE

9

1	EVALUATION, PEOPLE WILL TELL YOU EVERYTHING THEY
2	FEEL. THEN YOU DISTILL IT AND GO BACK. AND IF
3	THERE WAS A NEED FOR FURTHER DISCUSSION, YOU COULD
4	ALWAYS BRING A GROUP TOGETHER.
5	MR. KLEIN: SO
6	CHAIRPERSON LANSING: WE'RE NOT LOOKING
7	FOR CONSENSUS. WE'RE LOOKING FOR ACTUALLY THERE
8	MAY BE CONSENSUS, BUT FOR OPENNESS OF DISCUSSION.
9	MR. KLEIN: SO I'M PERCEIVING A DIFFERENCE
10	MAYBE ERRONEOUSLY IN SOME OF THE CONCEPTS. SO I'M
11	REALLY STATING THAT THE PRESIDENT OR I WOULD MEET
12	WITH THE ENTIRE BOARD IN A DISCUSSION.
13	CHAI RPERSON LANSI NG: ABSOLUTELY.
14	MR. KLEIN: SO ONCE THAT DISCUSSION TAKES
15	PLACE, YOU'RE SAYING THERE'S A SEPARATE STEP WHERE
16	YOU OR I THEN SUMMARIZE THE POINTS.
17	CHAI RPERSON LANSI NG: YES. AND THEN,
18	CLAIRE, YOU WANT TO SAY IT AGAIN?
19	DR. POMEROY: SO I THINK THAT I WANT TO
20	CLARIFY THAT MY EXPECTATION IS THAT ALL THREE OF
21	THESE PEOPLE WILL BE MEETING ON A REGULAR BASIS AND
22	GETTING INFORMAL FEEDBACK THROUGHOUT THE YEAR. THAT
23	HAVING BEEN SAID, I THINK THAT THERE WOULD BE A
24	CLOSED SESSION. EACH OF THESE THREE PEOPLE WOULD BE
25	CERTAINLY, YOU KNOW, ASKED TO PROVIDE ANY INPUT THEY

-	
1	WANT AND TAKE ANY QUESTIONS. BUT THEN THE
2	REPRESENTATIVE WOULD MEET IN CLOSED SESSION WITHOUT
3	THE PERSON BEING EVALUATED TO GET FEEDBACK,
4	SYNTHESIZE IT, AND THEN REPORT BACK A RATING AND
5	SUGGESTED AREAS FOR IMPROVEMENT, IF NECESSARY, SO
6	THAT YOU CAN HAVE A ONE-ON-ONE CONVERSATION WITH
7	THIS REPRESENTATIVE. BUT THEY WOULD BE REPORTING
8	THE ICOC BOARD'S BROAD INPUT.
9	MR. SHEEHY: CAN I ASK A QUESTION?
10	CHAI RPERSON LANSI NG: OF COURSE.
11	MR. SHEEHY: I REMEMBER SEEING FLOATING
12	AROUND, AND I ONLY REMEMBER IT BECAUSE IT'S WHAT I'M
13	VERY FAMILIAR WITH, THE STANDARD UC PERFORMANCE
14	EVALUATION TEMPLATE. WOULD THAT BE WHAT WE'D BE
15	WORKING OFF OF? IT SEEMS LIKE EVERYBODY USES I
16	DON'T KNOW. MAYBE DR. POMEROY KNOWS AT YOUR LEVELS.
17	AT MY LEVEL EVERYBODY SEEMS TO USE THOSE, AND
18	THEY'RE FAIRLY GOOD IN TERMS OF LANGUAGE AND AREAS.
19	IT DOES SEEM TO HAVE A NICE FEEL IT TO. I DON'T
20	KNOW IF THAT'S THE KIND OF TEMPLATE BECAUSE THIS
21	SOUNDS LIKE A BROADBASED DISCUSSION. THAT WOULD
22	GIVE US A LITTLE FOCUS.
23	MR. KLEIN: IT'S AN INTERESTING MODEL. IT
24	IS DIFFICULT AT TIMES TO SUMMARIZE ALL OF THESE
25	VIEWS ACCURATELY. BUT IF THE PERSON WHAT I'D
	11

1	LIKE TO DO IS HAVE A CHANCE TO THINK ABOUT THAT. I
2	THINK IT'S AN INTERESTING MODEL.
3	THE ONE ISSUE THAT I GET CONCERNED WITH IS
4	MAKING CERTAIN THAT IF I'M THE CONDUIT, THAT THE
5	WHOLE VALUE OF THIS COMMUNICATION IS COMING THROUGH,
6	AND MAYBE THERE'S A PROCESS FOR A WRITTEN EVALUATION
7	WHERE A SMALL GROUP OF THE BOARD CAN PROVIDE
8	ADDITIONAL COMMENTS TO A WRITTEN SUMMARY OR
9	SOMETHING SO THAT WE HAVE THE BENEFIT OF MAKING
10	CERTAIN WE ARE CAPTURING THE BREADTH OF OPINION.
11	CHAI RPERSON LANSI NG: I ALSO THI NK, YOU
12	KNOW, AND MAYBE I THINK WE CAN FORMALIZE THE
13	PROCESS, BUT IT'S LIKE A MARRIAGE. THE SECRET IS IN
14	THE COMMUNICATION, AND YOU DON'T JUST DO IT WHEN
15	THERE'S A PROCESS. BOB, AT ANY GIVEN TIME YOU AND I
16	ARE FREE TO TALK ABOUT ANYTHING WE WANT THAT'S NOT
17	VIOLATING BAGLEY-KEENE. YOU CAN SAY TO ME, SHERRY,
18	HOW DO YOU FEEL ABOUT THIS? OR I SAY, BOB, YOU
19	KNOW, AS CHAIR OF GOVERNANCE, WHAT DID YOU FEEL?
20	THAT'S OKAY. THAT'S NOT VIOLATING BAGLEY-KEENE.
21	NO ONE IS SAYING THAT AT ANY GIVEN TIME
22	YOU CAN'T GO TO EVERY SINGLE MEMBER OF THE BOARD AND
23	SAY, YOU KNOW, WHAT ARE YOU THINKING? AM I SERVING
24	YOUR NEEDS? THAT'S NOT VIOLATING BAGLEY-KEENE
25	UNLESS I'M NUTS. IT ISN'T.

1	AND SO ALL WE'RE TRYING TO SAY IS
2	BECAUSE YOU HAVE ACTUALLY REQUESTED THIS. THIS CAME
3	FROM YOU. WE DIDN'T AS FAR AS WE'RE CONCERNED,
4	WE WERE VERY HAPPY WITH THE INFORMAL DISCUSSIONS
5	THAT YOU AND I HAVE CONTINUED TO HAVE, HOW MANY
6	YEARS IS IT NOW, FIVE YEARS. WE CONTINUE TO HAVE
7	INFORMAL DISCUSSIONS AND HEALTHY DISAGREEMENTS AND
8	COMING TOGETHER WITH CONSENSUS. YOU ASKED FOR THIS.
9	SO WHAT WE'RE SAYING IS, OKAY, HERE'S WHAT
10	WE'LL DO. WE WILL GET TOGETHER, THE BOARD, WE'LL
11	GET INPUT FROM EVERYBODY. CLEARLY THE PERSON THAT'S
12	BEING EVALUATED CAN'T BE IN THE ROOM BECAUSE NOBODY
13	WILL TALK. IT'S JUST HUMAN NATURE. THEY WILL BE
14	SELF-CONSCIOUS.
15	THEN ONE PERSON WILL BE THE CONDUIT AND
16	EXPRESS THE DIVERSITY OF OPINION. BY THE WAY, I'LL
17	TAKE THE PREROGATIVE OF THE CHAIR TO SAY I DON'T
18	THINK THIS IS GOING TO BE A TRAUMATIC EVALUATION.
19	PEOPLE SEEM TO BE VERY HAPPY WITH EVERYBODY. BUT
20	SHOULD THERE BE A PROBLEM, IT WILL BE EXPRESSED.
21	BUT AT ANY GIVEN TIME, YOU, ALAN, ED, MYSELF, ANY
22	BOARD MEMBER CAN PICK UP A PHONE AND SAY, YOU KNOW
23	WHAT. I'M CONCERNED ABOUT THIS AND SIT AND TALK TO
24	YOU, AND THAT'S NOT VIOLATING BAGLEY-KEENE. YOU CAN
25	GO AROUND TO EVERY BOARD MEMBER AT ANY GIVEN TIME

13

1	AND SAY, HEY, AM I SERVING YOUR NEEDS RIGHT? THAT'S
2	NOT VIOLATING BAGLEY-KEENE.
3	MR. KLEIN: SURE. I ACTUALLY, SHERRY, SEE
4	A VALUE IN INDIVIDUAL BOARD MEMBERS TALKING DIRECTLY
5	TO THE PERSON IN THAT MEETING. AND, YOU KNOW, WE
6	WORK SO MANY HOURS TOGETHER. I HOPE THAT PEOPLE
7	JUST WILL BE OPEN BECAUSE IT'S VERY VALUABLE TO HAVE
8	A GIVE-AND-TAKE DISCUSSION OPENLY AND TRANSPARENTLY
9	WITH THESE VARIOUS COMPONENTS OF THE BOARD.
10	BUT, YOU KNOW, THIS IS A VERY THOUGHTFUL
11	IDEA. AND I WOULD JUST ASK THAT MAYBE WE COULD
12	THINK ABOUT
13	CHAI RPERSON LANSI NG: THERE'S NO URGENCY.
14	THIS WHOLE MEETING THAT WE'RE HAVING A DAY AND A
15	HALF BEFORE CHRISTMAS IS NOT URGENT ON ANY OF THESE
16	MATTERS. I THINK WE'RE MAKING THIS PROPOSAL. WE'D
17	LIKE MORE COMMENTS FROM THE SUBCOMMITTEE AND THE
18	PUBLIC. BY THE WAY, CLAIRE, THERE WILL BE TWO
19	STEPS. YOU CAN COME INTO A PUBLIC MEETING AND GET
20	INPUT AND HAVE AN OPEN SESSION, THEN WE CAN GO INTO
21	A CLOSED SESSION. AND IF SOMEBODY HAD SOMETHING
22	THEY DIDN'T WANT TO SAY, THEY COULD SAY IT THEN.
23	IN CORPORATE BOARDS THAT I'M ON, WE
24	ACTUALLY DO IT THAT WAY. WE GO INTO AN OPEN
25	SESSION, THEN THE OFFICERS LEAVE, AND WE GO INTO
	1/

14

1	WHAT'S CALLED AN EXECUTIVE SESSION. AND SOMEBODY
2	WILL SAY I DIDN'T WANT TO SAY THIS, BLAH, BLAH,
3	BLAH. AND THEN THERE'S ALWAYS THE PERSON WHO HAS TO
4	GO AND DELIVER THE BAD NEWS. SO WE CAN DO IT IN
5	THAT WAY.
6	MR. KLEIN: THAT MIGHT WORK WELL.
7	CHAIRPERSON LANSING: MAYBE LET'S HEAR
8	MORE COMMENTS, AND MAYBE, CLAIRE, TALK THIS AROUND A
9	LITTLE BIT MORE AND THINK ABOUT THIS. WE DON'T HAVE
10	TO COME TO A CONCLUSION TODAY, BUT I'M NOT OBJECTING
11	TO THOSE TWO STEPS.
12	DR. POMEROY: BEFORE THE PEOPLE COMMENT, I
13	MIGHT JUST SAY I THINK IT'S VERY THAT WOULD BE
14	VERY APPROPRIATE, BUT I DON'T THINK IT'S FAIR TO THE
15	PEOPLE IN THESE POSITIONS TO GET 29 DIFFERENT
16	PERFORMANCE EVALUATIONS ULTIMATELY. THERE HAS TO BE
17	ONE FINAL PERFORMANCE EVALUATION. THAT'S DIFFERENT
18	THAN GETTING FEEDBACK FROM EVERYONE ABOUT HOW YOU
19	CAN DO YOUR JOB BETTER.
20	CHAI RPERSON LANSI NG: YOU CAN DO THAT ANY
21	TIME YOU WANT.
22	MR. KLEIN: SO I THINK SHERRY'S CORPORATE
23	MODEL WITH BOTH STEPS IS VERY HELPFUL. AND WHY
24	DON'T WE, SHERRY, JUST GIVE PEOPLE A CHANCE TO THINK
25	ABOUT THI S.

1	CHAI RPERSON LANSI NG: THAT'S OKAY. ARE
2	THERE ANY MORE COMMENTS FROM MEMBERS OF THE
3	SUBCOMMI TTEE?
4	DR. FONTANA: I'M LIKING THE CORPORATE
5	MODEL. AND MY ONLY OTHER COMMENT WAS INSTEAD OF THE
6	ONE PERSON GIVING BACK THE RESPONSE, THAT PERHAPS
7	THERE SHOULD BE TWO OR THREE. JUST WHEN YOU' RE
8	HEARING 29 PEOPLE AND TO SUMMARIZE THAT.
9	CHAI RPERSON LANSING: THAT'S FAIR.
10	DR. FONTANA: JUST A COUPLE, NOT A BIG
11	COMMITTEE, JUST A COUPLE PEOPLE THAT WOULD ALSO HELP
12	IN THAT FEEDBACK. AND THEN ALSO IN THE MODEL, AND I
13	UNDERSTAND HOW THE CEO WOULD GIVE THE FEEDBACK TO
14	THE PRESIDENT, WHO GIVES THE HOW WOULD THIS
15	MODEL
16	DR. POMEROY: THE CHAIR GIVES THE FEEDBACK
17	TO THE PRESIDENT. THE PRESIDENT IS THE CEO.
18	DR. FONTANA: I'M THINKING THE PRESIDENT
19	IS ALAN TROUNSON AND THE CEO IS BOB.
20	MR. KLEIN: NO. NO. THE CHAIR
21	DR. FONTANA: I'M SORRY.
22	MR. KLEIN: OTHER THAN MY FUNCTIONS IN
23	LAW, FINANCE, AND GOVERNMENT, THE PRESIDENT IS THE
24	CEO. AND AS THE CHAIR, I WOULD SAY, I THINK SHERRY
25	IS SAYING HERE, BUT I DON'T KNOW IF YOU CAN HEAR
	16
	IO

1	HER, THAT IT'S A FAIR COMMENT TO HAVE TWO OR THREE
2	PEOPLE. THAT WAY YOU GET SOME DEPTH AND SOME
3	VARIATION TO THE FEEDBACK.
4	CHAI RPERSON LANSI NG: CLAI RE, AGAI N
5	DR. POMEROY: THAT SOUNDS VERY REASONABLE.
6	CHAI RPERSON LANSI NG: VERY REASONABLE. I
7	THINK THAT'S A GOOD POINT, JEANNIE.
8	DR. FONTANA: COULD YOU JUST HELP ME
9	CLARIFY THE BEGINNING OF THIS WHOLE PRESENTATION
10	WE'RE TALKING ABOUT PERFORMANCE EVALUATIONS, AND I
11	HAVE THREE LISTED.
12	DR. POMEROY: CHAIR, VICE CHAIR, AND
13	PRESI DENT.
14	DR. FONTANA: SO THEN WHO IS EVALUATING
15	WHOM?
16	DR. POMEROY: SO JUST TO REITERATE, ALL
17	THREE OF THESE POSITIONS REPORT TO THE ICOC. THE
18	WHOLE ICOC IS EVALUATING ALL THREE OF THESE
19	POSITIONS. THAT'S WHY WE GET TOGETHER. THEN THE
20	FINAL REPORT IS DELIVERED TO THE PRESIDENT BY THE
21	CHAIR OF THE ICOC MAYBE WITH A COUPLE OF ADDITIONAL
22	PEOPLE, AS YOU' VE SUGGESTED. AND THEN FOR THE CHAIR
23	AND VICE CHAIR, FINAL REPORT IS DELIVERED BY THE
24	CHAIR OF THE GOVERNANCE SUBCOMMITTEE PLUS OR MINUS A
25	COUPLE OF ADDITIONAL PEOPLE AS WE TALKED ABOUT.

17

-	
1	DR. FONTANA: THAT'S GREAT.
2	MR. KLEIN: ON THE VICE CHAIR, CLAIRE,
3	SINCE UNDER THE INITIATIVE, THE VICE CHAIR,
4	STATUTORILY THEIR DUTIES ARE TO SUPPORT THE CHAIR IN
5	THEIR FUNCTION, MAKING SURE THAT THOSE FUNCTIONS ARE
6	BEING FULFILLED FOR THE CHAIR, I THINK THAT ONE OF
7	THOSE THREE PEOPLE NEEDS TO BE THE CHAIR BECAUSE THE
8	CHAIR IS THE ONE THAT INTERFACES WITH HIM EVERY DAY
9	IN TERMS OF WHETHER THOSE FUNCTIONS ARE BEING
10	FULFILLED. THERE'S ASSIGNMENTS FROM THE CHAIR TO
11	THE VICE CHAIR OF FUNCTIONS THAT ARE CONSTANTLY IN
12	REAL TIME CHANGING. IT'S MORE OF A TEAM EFFORT.
13	DR. POMEROY: THAT SOUNDS REASONABLE TO ME
14	PERSONALLY. WE'LL LET EVERYONE COMMENT ON THAT, BUT
15	THAT SOUNDS REASONABLE TO ME.
16	DR. FONTANA: ME TOO.
17	MS. KING: SHERRY, IF THERE ARE NO OTHER
18	COMMENTS FROM MEMBERS OF THE BOARD, WE HAVE ACTUALLY
19	HAVE SOME STAFF MEMBERS IN SAN FRANCISCO. I KNOW AT
20	LEAST PRESIDENT TROUNSON. I WASN'T SURE IF ANYONE
21	ELSE HAD A COMMENT. I JUST WANTED TO MAKE SURE YOU
22	WERE AWARE OF THAT.
23	CHAIRPERSON LANSING: I WOULD LIKE TO HEAR
24	COMMENTS FROM ANYONE ELSE WHO WOULD LIKE TO SPEAK
25	BEFORE I GO TO MEMBERS OF THE PUBLIC, STAFF IN ANY
	18

WAY. 1 DR. TROUNSON: IT'S NICE TO BE HERE, 2 EVERYBODY. YOU KNOW, I HAVE NO PROBLEM WITH 3 CLAIRE'S PROPOSAL. THE ONLY THING THAT I THINK WE 4 NEED TO DO FOR CERTAIN IS TO ESTABLISH GOALS SO THAT 5 THERE IS SOME SUBSTANCE TO WHICH THE REVIEW WILL BE 6 7 MADE AFTER A PERIOD OF TIME. AND SO THOSE GOALS 8 NEED TO BE VERY CLEAR. AT THE MOMENT I SEE THE MISSION AS THE PRIMARY GOAL, BUT THERE MAY BE 9 10 SUBSIDIARY GOALS THAT NEED TO BE SPELLED OUT WITHIN THAT THAT YOU WOULD THEN BE RANKED AGAINST. 11 I THINK IF THERE'S SOME CLARITY ON THE WAY 12 13 THE JUDGMENT WOULD BE MADE, THEN I THINK IT'S A VERY WORKABLE PROCEDURE. 14 AND THE ONLY THING I THINK, IF YOU ARE 15 16 GOING TO HAVE THREE PEOPLE, YOU MIGHT WANT TO ASK 17 THE PRESIDENT OR THE CHAIR WHETHER THEY HAVE A PREFERENCE FOR ONE OR OTHER OF THE PEOPLE THAT MIGHT 18 19 BE DOING IT. IT JUST COULD TURN OUT IN A SMALL GROUP OF PEOPLE SOME PEOPLE YOU DIDN'T GET ALONG 20 21 APART FROM THAT, I THINK IT'S A PERFECTLY WITH. 22 GOOD WAY OF DOING IT. DR. POMEROY: THE WHOLE CONCEPT OF THIS 23 WAS TO GIVE DEFINED DELIVERABLES TO HELP YOU AND THE 24 CHAIR AND THE VICE CHAIR. AND I WOULD SUGGEST THAT 25 19

1	THE CONSTITUTION OF WHO THE TWO TO THREE PEOPLE ARE
2	WOULD BE AN ICOC DECISION. USUALLY PEOPLE DON'T
3	PICK OUT THEIR OWN EVALUATORS.
4	CHAIRPERSON LANSING: I AGREE WITH THAT.
5	NOW CAN I TURN TO COMMENTS FROM MEMBERS OF
6	THE PUBLIC BECAUSE I DON'T THINK WE'RE READY TO TAKE
7	A VOTE ON THIS. I THINK WHAT WE NEED TO DO, CLAIRE,
8	UNLESS YOU DISAGREE, I THINK WE GOT GOOD INPUT, AND
9	I THINK WE NEED TO COME BACK WITH ANOTHER PROPOSAL,
10	HEARING THE INPUT ABOUT POSSIBLY TWO STEPS AND ALSO
11	HEARING THE INPUT ABOUT NOT ONE PERSON, BUT THREE
12	PEOPLE, AND KIND OF COME UP WITH A PROPOSAL THAT WE
13	CAN CIRCULATE.
14	DR. POMEROY: SOUNDS GOOD.
15	CHAIRPERSON LANSING: OKAY. I'D LIKE TO
16	GO TO CIRM IN SAN FRANCISCO. IS THERE ANYTHING FROM
17	THE PUBLIC THERE?
18	MS. KING: YES, WE DO.
19	MR. REED: THIS IS DON REED. I'M NOT SURE
20	IF THIS FITS HERE OR NO. 4, CONSIDERATION OF
21	AMENDMENTS TO CIRM INTERNAL GOVERNANCE POLICY.
22	LOOKING AT THE JOB DESCRIPTION OF THE CHAIR, VICE
23	CHAIR, AND THE PRESIDENT, AND IN NONE OF THEM DO I
24	SEE ANYTHING ABOUT BEING THE FACE OF THE CIRM TO THE
25	PUBLIC. I THINK THAT'S SOMETHING THAT SHOULD BE A
	20

20

CONSTANT REMINDER FOR EACH OF THESE THREE PEOPLE TO
REACH OUT FIRST TO THE COMMUNITY SO THEY CAN HEAR
FROM US AND NOT ONLY WHEN WE'RE REACTING TO THE
LATEST ATTACK.
SO I THINK THAT WE NEED TO MAYBE WORK OUT
SOMETHING, A MINUTE FOR STEM CELLS OR SOMETHING. I
ALWAYS LOVE IT WHEN PRESIDENT TROUNSON BEGINS BY
TALKING A LITTLE BIT ABOUT THE LATEST SCIENCE. THE
PUBLIC NEEDS TO HEAR THAT.
I THINK EACH PERSON'S JOB DESCRIPTION
SHOULD BE A REMINDER AND A PROMISE THAT THEY ARE THE
FACE OF THE CIRM AND TO SYSTEMATICALLY SERVE THE
PUBLIC SO THE PUBLIC CAN KNOW WHAT WE'RE DOING AND
NOT JUST ANSWER TO ATTACKS.
CHAI RPERSON LANSI NG: THANK YOU, DON.
THAT'S A GOOD POINT. UC DAVIS?
DR. POMEROY: NO PUBLIC.
CHAI RPERSON LANSI NG: LANCELOT LANE?
DR. FONTANA: YES, WE HAVE A COMMENT.
MR. ADAMS: HI, IT'S BILL ADAMS,
INTERNATIONAL STEM CELL. I THINK THIS PROCESS
SHOULD BE HELD TO THE SAME STANDARD AS PUBLIC
CORPORATIONS LIKE OURS WHERE OUR OUTSIDE DIRECTORS
FORM A COMMITTEE, AND GUYS LIKE ME HAVE TO GO IN AND
SCRIMP AND SCRAPE TO GET MY SALARY RENEWED EVERY
21

21

1	YEAR. I JUST THINK IT MAKES SENSE. AND I THINK
2	YOU'LL WANT TWO OR THREE PEOPLE BECAUSE YOU
3	CERTAINLY CAN'T HAVE 29.
4	MY OTHER QUESTION IS HOW ARE THE
5	EVALUATIONS GOING TO TAKE PLACE FOR THE REST OF THE
6	STAFF OF CIRM?
7	DR. POMEROY: THE REST OF THE STAFF REPORT
8	TO THE PRESIDENT, AND THE PRESIDENT THAT'S
9	OUTLINED IN THE INTERNAL GOVERNANCE POLICY. AND THE
10	PRESIDENT WILL DO THEIR EVALUATIONS EITHER DIRECTLY
11	OR THROUGH THE SENIOR OFFICERS TO WHICH THEY
12	REPORT THROUGH WHICH THEY REPORT. AND THERE
13	ACTUALLY IS A FORM AND A PROCESS BY WHICH THE REST
14	OF THE STAFF ARE EVALUATED.
15	DR. TROUNSON: CLAIRE, THAT'S JUST BEING
16	COMPLETED AT THE PRESENT TIME. IT'S, YOU KNOW,
17	WITHIN ONE OR TWO STAFF. THE REST HAVE BEEN ALL
18	THROUGH THE STAFF APPRAISAL SYSTEM.
19	MR. KLEIN: AND I'D LIKE TO SAY THAT THE
20	APPRAISAL SYSTEM THEY PUT TOGETHER IS NOT ISOLATED
21	TO THE IMMEDIATE SUPERVISOR. IT INCLUDES WHAT THEY
22	CALL A 360 OVERVIEW SO THAT INCORPORATING COMMENTS
23	FROM MORE THAN THE DIRECT SUPERVISOR, INCLUDING
24	PEOPLE WHERE THERE ARE PRIMARY, SECONDARY, AND
25	TERTIARY CONTACTS, SO THAT YOU GET A DIVERSITY OF

22

1	OPINION, SO YOU HAVE A BALANCED OUTCOME BASED UPON
2	ALL THE VARIOUS PRIMARY AND LAYERS OF SECONDARY,
3	PROPER WAY TO PUT IT, REPORTING AND FUNCTIONAL
4	INTERFACE.
5	CHAIRPERSON LANSING: THANK YOU. IRVINE,
6	PUBLI C?
7	DR. STEWARD: NO PUBLIC.
8	MR. ADAMS: ONE LAST THING. WITH THE
9	EXCEPTION OF THE THREE, THEN THE PUBLIC WOULD HAVE
10	NO INPUT ON ANY OF THE SENIOR STAFF MEMBERS; IS THAT
11	CORRECT?
12	DR. POMEROY: ALAN, YOU WANT TO ADDRESS
13	THAT ONE?
14	DR. TROUNSON: THERE HASN'T BEEN THERE
15	HASN'T BEEN ANY INVOLVEMENT BEYOND THE SUPERVISORS
16	AND THE 360 DEGREES OF THREE OR FOUR PEOPLE WHO
17	SURROUND THAT INDIVIDUAL IN THEIR CONTACTS. THAT
18	HASN' T BEEN PART OF THE CURRENT STAFF APPRAI SAL
19	SYSTEM, NO.
20	DR. POMEROY: AND THAT I MIGHT JUST
21	COMMENT, ALAN, THAT WOULD BE CONSISTENT WITH THE
22	APPROACH THAT'S USED IN THE UNIVERSITY OF CALIFORNIA
23	AND OTHER AGENCIES.
24	DR. TROUNSON: THANK YOU.
25	CHAI RPERSON LANSI NG: CONNECT?
	23

1	MR. ROTH: NO COMMENTS HERE.
2	CHAI RPERSON LANSI NG: LOS ANGELES?
3	MR. SIMPSON: JOHN SIMPSON, CONSUMER
4	WATCHDOG. I JUST WANTED TO AGREE AND UNDERSCORE DR.
5	TROUNSON'S POINT OF THE IMPORTANCE OF CLEAR GOALS
6	BEING ESTABLISHED. ALSO I WAS ABOUT TO SUGGEST THE
7	SAME THING THAT DR. FONTANA SUGGESTED, MORE THAN
8	ONE, BUT LESS THAN THREE, THREE OR LESS.
9	SOMETHING I'D LIKE TO ADD IS THE NOTION
10	THAT SOME SORT OF PUBLIC SYNOPSIS OF THE EVALUATION
11	THAT IS RELEASED IN SOME FORM OR ANOTHER AFTER IT'S
12	DONE. I THINK THAT'S IMPORTANT. IT COULD BE AKIN
13	TO THE WAY YOU DO SUMMARIES ON YOUR GRANT REQUESTS,
14	BUT I THINK THAT IT WOULD BE GOOD TO HAVE SOME SORT
15	OF DISTILLED, CLEAR PUBLIC SUMMARY OF THE
16	EVALUATI ON.
17	CHAIRPERSON LANSING: SO WHAT I'D LIKE TO
18	SUGGEST IS THAT WE'VE NOW HEARD ALL THE COMMENTS.
19	AND, CLAIRE, I THINK WE SHOULD GO BACK AND TRY AND
20	DISTILL EVERYTHING THAT WE'VE HEARD AND COME BACK
21	WITH ANOTHER RECOMMENDATION AS TO HOW TO TACKLE THE
22	SI TUATI ON.
23	DR. POMEROY: I THINK THIS HAS BEEN VERY
24	HELPFUL, AND WE CAN ACTUALLY, NOW THAT WE HAVE ALL
25	THIS INPUT, PREPARE SOMETHING IN WRITING FOR A
	24

1	
1	FORMAL CONSIDERATION BY THE COMMITTEE.
2	CHAI RPERSON LANSI NG: YES, JOHN.
3	MR. SIMPSON: JOHN SIMPSON AGAIN FROM
4	CONSUMER WATCHDOG. IT JUST OCCURS TO ME THAT IT'S
5	CRITICALLY IMPORTANT THAT AS YOU GO THROUGH WITH
6	THIS VERY IMPORTANT PROCESS, THAT YOU FOCUS ON THE
7	PROCESS AND THE STRUCTURES AND DON'T THINK ABOUT
8	INDIVIDUALS WHO HOLD THE POSITIONS NOW. YOU SHOULD
9	BE THINKING PRIMARILY ABOUT PROCESS AND STRUCTURE,
10	WHICH I SENSE IS WHAT YOU ARE TRYING TO DO, BUT I
11	JUST WANTED TO UNDERSCORE IT.
12	CHAIRPERSON LANSING: IT IS A VERY GOOD
13	POINT, AND WE'RE THINKING ABOUT THE JOBS, NOT THE
14	PEOPLE. THAT'S WHY WE'RE DOING THIS. I THINK
15	THAT'S A VERY IMPORTANT THING.
16	WITH THAT, THEN, I THINK, AM I RIGHT, I'M
17	MOVING TO AGENDA ITEM NO. 4, WHICH IS CONSIDERATION,
18	AGAIN, OF AMENDMENTS TO CIRM'S INTERNAL GOVERNANCE
19	POLICY, AND THESE ARE ALL LINKED TOGETHER. SO,
20	AGAIN, CLAIRE, I'D LIKE YOU TO WALK US THROUGH SOME
21	OF THE POSSIBLE MODIFICATIONS.
22	DR. POMEROY: SO THE INTERNAL GOVERNANCE
23	POLICY HAS KIND OF BEEN A LIVING DOCUMENT, THE
24	HISTORY OF THE CIRM. AND IN LIGHT OF THAT, WE
25	WANTED TO ASK FOR INPUT ON SEVERAL ASPECTS OF IT.
	25

1	FIRST OF ALL, FOR THOSE OF YOU WHO HAVE IT
2	IN FRONT OF YOU, SECTION 1 TALKS ABOUT THE
3	ORGANIZATION OF CIRM AND JOB RESPONSIBILITIES. AND
4	NOW WOULD BE THE APPROPRIATE TIME TO GO THROUGH
5	THOSE, SHERRY.
6	CHAI RPERSON: YES.
7	DR. POMEROY: SO WE WOULD SUGGEST SOME
8	MODIFICATIONS. THE CHAIRPERSON OF THE ICOC'S
9	PRIMARY RESPONSIBILITIES ARE THE FIRST THING
10	DISCUSSED. AND THAT I WANT TO JUST GIVE AN OVERVIEW
11	OF THIS. IT'S TO MANAGE THE ICOC'S AGENDA AND WORK
12	FLOW, INCLUDING THE EVALUATIONS AND APPROVALS FOR
13	THE CIRM RESEARCH GRANTS AND LOANS, FACILITIES
14	GRANTS, APPROVAL OF THE RESEARCH AND ETHICAL
15	STANDARDS FOR THE RECIPIENTS OF THOSE GRANTS.
16	TO SUPERVISE THE PUBLIC ACCOUNTABILITY
17	REQUIREMENTS FOR THE ICOC AND SUBCOMMITTEES, AND
18	THAT INCLUDES COMPLIANCE AND LEGAL AND FINANCIAL
19	ACCOUNTABILITY OF THE ICOC. AND FURTHER
20	CLARIFICATION FROM THE PREVIOUS VERSION, WE WOULD
21	SUGGEST SPECIFICALLY POINTING OUT THAT THIS INCLUDES
22	TRAVEL AND EXPENSE REIMBURSEMENT POLICIES FOR ICOC
23	MEMBERS.
24	THAT THIRDLY, THE CHAIR WOULD BE
25	RESPONSIBLE FOR GUIDING THE ICOC AND SUPERVISING THE
	24
	26

1	CIRM ANNUAL REPORT AND THE ANNUAL INDEPENDENT
2	FINANCIAL AUDIT. THAT THE CHAIR WOULD GUIDE THE
3	ICOC IN DEVELOPING AND IMPLEMENTING THE CIRM
4	STRATEGIC EXTERNAL FINANCIAL PLAN. THAT'S WORDING
5	THAT'S TAKEN FROM PROPOSITION 71. AND THAT WOULD
6	INCLUDE OPTIMIZING FINANCIAL LEVERAGE OPPORTUNITIES.
7	THE CHAIR WOULD ALSO GUIDE THE ICOC IN
8	ESTABLISHING POLICIES FOR THE ICOC'S LEGISLATIVE
9	ADVOCACY. AND IT WOULD BE EXPECTED THAT THIS WOULD
10	BE DONE IN PARTNERSHIP WITH THE CIRM PRESIDENT AND
11	IN ACCORD WITH ALL LAWS AND REGULATIONS RESTRICTING
12	POLITICAL ACTIVITIES OF STATE EMPLOYEES.
13	THE CHAIR WOULD ALSO REPORT TO THE
14	CITIZENS FINANCIAL ACCOUNTABILITY OVERSIGHT
15	COMMITTEE REGARDING THE AUDIT AND THE FINANCIAL
16	PRACTICES AND PERFORMANCE OF CIRM. WOULD SERVE AS A
17	MEMBER OF THE CALIFORNIA STEM CELL RESEARCH AND
18	CURES FINANCE COMMITTEE, AND AS OUTLINED IN PROP 71,
19	APPOINT TWO MEMBERS OF THE ICOC TO THE COMMITTEE AND
20	WORK WITH THE STATE TREASURER'S OFFICE, THE
21	CONTROLLER'S OFFICE, AND THE DIRECTOR OF THE
22	DEPARTMENT OF FINANCE ON THE STRUCTURE OF THE BOND
23	FINANCING.
24	THE PRESIDENT WOULD SORRY THE CHAIR
25	WOULD LEAD NEGOTIATIONS FOR INTELLECTUAL PROPERTY
	27

OF THE ICOC. SO THAT'S A CLARIFICATION PROPOSED OF THE CHAIR'S DUTIES. AND IF I CAN JUST GO ON TO THE TWO POSITIONS, I THINK IT MIGHT HELP IF I JUST RUN THROUGH THE WHOLE THING. THE VICE CHAIR'S RESPONSIBILITIES, WE
SO THAT'S A CLARIFICATION PROPOSED OF THE CHAIR'S DUTIES. AND IF I CAN JUST GO ON TO THE TWO POSITIONS, I THINK IT MIGHT HELP IF I JUST RUN
SO THAT'S A CLARIFICATION PROPOSED OF THE CHAIR'S DUTIES. AND IF I CAN JUST GO ON TO THE TWO
SO THAT'S A CLARIFICATION PROPOSED OF THE
OF THE ICOC.
DELEGATED TO THE VICE CHAIR OR OTHERS WITH APPROVAL
AND IT POINTS OUT THAT THESE DUTIES CAN BE
I COC.
POLICY AND PERFORM OTHER DUTIES AS ASSIGNED BY THE
SECTION. TO COMPLY WITH THE INTERNAL GOVERNANCE
AGAIN, THAT'S WHAT WE JUST DISCUSSED IN THE FIRST
PERFORMANCE EVALUATIONS OF THE CIRM PRESIDENT.
AND COMMUNICATE THE ANNUAL OBJECTIVES AND
TO PREPARE, OBTAIN APPROVAL FROM THE ICOC
CIRM OFFICE OF THE CHAIR.
71, AND TO MANAGE THE INTERNAL OPERATIONS OF THE
FACILITIES WORKING GROUP, AGAIN AS OUTLINED IN PROP
AS A MEMBER OF THE STANDARDS WORKING GROUP AND THE
AS EX OFFICIO MEMBER OF THE GRANTS WORKING GROUP AND
THE ICOC EXECUTIVE COMMITTEE MEETINGS, AND TO SERVE
RESPONSIBILITY TO MAKE SURE IT HAPPENS. TO CHAIR
BE DONE AGAIN, BUT IT IS ULTIMATELY THE CHAIR'S
PREVIOUSLY DELEGATED TO THE VICE CHAIR. THAT COULD
AGREEMENTS, POLICIES, AND CONTRACT TERMS. THIS WAS
P

1	WOULD PROPOSE, ARE, AGAIN, TO REPORT TO THE ICOC AND
2	ASSIST THE CHAIR IN CARRYING OUT HIS OR HER DUTIES.
3	TO PARTICIPATE IN THE ICOC EXECUTIVE COMMITTEE
4	MEETING AND TO COMPLY WITH THE INTERNAL GOVERNANCE
5	POLICY, AND PERFORM OTHER DUTIES AS ASSIGNED BY THE
6	I COC.
7	SO THE VICE CHAIR POSITION IS ACTUALLY
8	VERY EASY. IT'S TO ASSIST THE CHAIR IN CARRYING OUT
9	ALL OF THE DUTIES WE DISCUSSED FOR THE CHAIR.
10	FINALLY, THE PRESIDENT. THE PRESIDENT'S
11	PRIMARY RESPONSIBILITIES ARE TO SERVE AS THE CHIEF
12	EXECUTIVE OF CIRM AND TO REPORT TO THE ICOC. TO
13	DEVELOP, RECEIVE ICOC APPROVAL FOR, AND IMPLEMENT
14	THE STRATEGIC PLAN, EXCLUDING THE STRATEGIC EXTERNAL
15	FINANCE PLAN FOR CIRM, AND TO COMMUNICATE THE
16	VISION, MISSION, AND PROGRAMS OF CIRM TO EXTERNAL
17	CONSTITUENCIES. THAT GOES TO AN EARLIER COMMENT.
18	TO LEAD THE IMPLEMENTATION OF ALL CIRM
19	PROGRAMS AND POLICIES AND TO OVERSEE AND MANAGE ALL
20	CIRM OPERATIONS AND ACTIVITIES. TO HIRE, DIRECT,
21	AND MANAGE THE STAFF OF CIRM, AND TO HIRE AND
22	OVERSEE CONSULTANTS AS NEEDED. TO DEVELOP, OVERSEE,
23	AND MANAGE THE BUDGETS OF CIRM. TO EXECUTE AND
24	MANAGE ALL INTELLECTUAL PROPERTY AGREEMENTS AND ANY
25	OTHER CONTRACTS PERTAINING TO CIRM AND THE RESEARCH

IT FUNDS.

1

2 TO COORDINATE WITH STATE AND FEDERAL GOVERNMENT OFFICIALS REGARDING THE IMPLEMENTATION OF 3 CIRM'S PROGRAMS WITH THE EXCEPTION OF THE EXTERNAL 4 FINANCIAL STRATEGIES. TO DEVELOP AND IMPLEMENT 5 CIRM'S RELATIONSHIP WITH PATIENT ADVOCACY GROUPS. 6 7 ACADEMIC AND INDUSTRY PARTNERS, AND NATIONAL AND INTERNATIONAL SCIENTIFIC ORGANIZATIONS. TO RECRUIT 8 9 THE EXTERNAL, THAT IS THE NON-ICOC, MEMBERSHIP OF 10 THE WORKING GROUPS, AND TO DIRECT AND PARTICIPATE IN THE PROCESS OF SUPPORTING THE WORKING GROUP 11 12 REQUIREMENTS TO DEVELOP RECOMMENDATIONS ON GRANTS, 13 LOANS, FACILITIES, AND STANDARDS. AND TO DEVELOP AND IMPLEMENT CIRM'S 14 DIVERSITY POLICIES, TO PARTICIPATE IN ICOC EXECUTIVE 15 16 COMMITTEE MEETINGS, AND TO COMPLY WITH THE INTERNAL 17 GOVERNANCE POLICY, AND PERFORM OTHER DUTIES AS ASSIGNED BY THE ICOC. 18 19 AND, SHERRY, THAT COMPLETES OUR RECOMMENDATIONS ON THE PORTION OF THE INTERNAL 20 21 GOVERNANCE POLICY RELATED TO THE JOB DESCRIPTIONS. 22 AND I'M GOING TO STOP THERE AND THEN LATER RESUME WITH SOME GENERAL COMMENTS ABOUT THE REMAINING 23 24 PARTS. 25 CHAIRPERSON LANSING: ALL RIGHT. SO I'D 30

1	LIKE TO HEAR IF THERE'S ANY COMMENTS FROM ANY
2	MEMBERS OF THE SUBCOMMITTEE.
3	MR. KLEIN: THIS IS BOB. FIRST OF ALL,
4	CLAIRE, OBVIOUSLY YOU PUT A LOT OF THOUGHT INTO
5	THIS. AND IT'S DIFFICULT TO FOLLOW ALL OF THAT
6	WITHOUT A MARKED-UP VERSION, SO I THINK IT WOULD BE
7	HELPFUL FOR EVERYONE TO HAVE A MARKED-UP VERSION.
8	IT WOULD ALSO PROBABLY BE HELPFUL TO EVERYONE,
9	INCLUDING THE SUBCOMMITTEE MEMBERS, TO HAVE A COPY
10	OF, SHERRY, WHAT YOU ASKED ALAN AND I TO DO ABOUT
11	THREE MONTHS AGO, WHICH IS OUR JOB DESCRIPTION OF
12	THE CHAIR AND THE PRESIDENT, WHICH ALAN REVIEWED
13	MINE AND MADE COMMENTS, I MADE CHANGES, I REVIEWED
14	ALAN'S, HE MADE COMMENTS AND CHANGES. SO THOSE TWO
15	JOB DESCRIPTIONS KNIT TOGETHER TO MAKE SURE WE
16	COVERED THE WHOLE AREA.
17	AND I THINK IT WOULD BE HELPFUL TO
18	EVERYONE, INCLUDING THE PUBLIC, TO LOOK AT THOSE AND
19	HOW THEY WORK TOGETHER BECAUSE IN THE DAY-TO-DAY
20	OPERATION, THERE ARE AREAS THAT ARE NOT YET THAT
21	ARE NOT DETAILED INTO THE INITIATIVE WHICH SOMEBODY
22	HAS TO COVER, AND THE JOB DESCRIPTIONS ARE MORE
23	COMPLETE. SO I THINK GIVING THE PUBLIC AND THE
24	COMMITTEE MEMBERS COPIES OF THOSE WOULD BE HELPFUL
25	TO EVALUATE.

31

1	DR. POMEROY: SHERRY, IF I MIGHT JUST
2	CLARIFY, THAT WE REALLY WANTED TO HAVE A DISCUSSION
3	ABOUT THIS AND GET INPUT BEFORE WE HAD A FINAL
4	VERSION. THAT'S THE FIRST COMMENT. AND, OF COURSE,
5	AS SOON AS WE GET THAT INPUT, WE WILL PUT OUT A
6	WRITTEN VERSION.
7	SECOND OF ALL, THE PRINCIPLE THAT WE USED
8	WAS TO REALLY DEFINE THE RESPONSIBILITIES AS
9	OUTLINED IN PROP 71, AND THAT THE MORE SPECIFICS
10	COULD BE PROVIDED BY THE ANNUAL OBJECTIVES AND
11	DELIVERABLES THAT WE TALKED ABOUT PREVIOUSLY.
12	CHAI RPERSON. LANSI NG: ALL RIGHT.
13	DR. FONTANA: I HAVE A COMMENT. I HATE TO
14	BRING THIS UP, BUT, YOU KNOW, WHEN IT'S SPELLED OUT
15	SO BEAUTIFULLY IN FRONT OF US THE JOB DESCRIPTION OF
16	THE CHAIR, IT'S HARD TO IMAGINE THAT THIS IS A
17	PART-TIME POSITION.
18	CHAI RPERSON LANSI NG: WELL, UNFORTUNATELY
19	IT IS. BUT WE ALL ACCEPTED THAT. I RESPECT YOUR
20	OPINION. I UNDERSTAND WHAT YOU'RE SAYING.
21	MR. SHEEHY: OKAY. I WANT TO GO BACK TO
22	THE DUTIES OF THE PRESIDENT. AND THERE WAS A
23	MENTION OF THE STRATEGIC PLAN. COULD YOU REPEAT
24	THAT FOR ME, AND THEN COULD I MAKE A COMMENT ON IT?
25	DR. POMEROY: OKAY. TO RECEIVE I COC
	32
	52

1	APPROVAL FOR AND IMPLEMENT THE STRATEGIC PLAN,
2	EXCLUDING THE STRATEGIC EXTERNAL FINANCIAL PLAN.
3	MR. SHEEHY: SO WHERE IS IT IF I
4	REMEMBER PROP 71, THE DEVELOPMENT OF THE STRATEGIC
5	PLAN IS A DUTY OF THE ICOC.
6	DR. POMEROY: YES. AND I AGREE WITH THAT.
7	AND THAT'S SO I THINK THE QUESTION REALLY COMES
8	DOWN TO, JEFF, A SPECIFIC OF HOW THE PRESIDENT WOULD
9	RECEIVE ICOC APPROVAL OF THE PLAN. I HEAR WHAT
10	YOU'RE SAYING. BUT I ALSO THINK THAT I WOULD JUST
11	SUGGEST THAT THE PRESIDENT MIGHT WANT TO BE THE SORT
12	OF THE PERSON WHO PUTS TOGETHER ALL THE INPUT
13	THAT THE ICOC GIVES AND DRAWS UP SOMETHING FOR THE
14	ICOC TO RESPOND TO. BUT ULTIMATELY THE ICOC HAS TO
15	APPROVE IT.
16	MR. SHEEHY: CAN I MAKE BECAUSE AND
17	I REALLY THOUGHT THAT ZACH DID A TREMENDOUS JOB THE
18	FIRST GO-AROUND. I THINK WE ALL RECOGNIZE THAT THE
19	EXPERTISE TO DEVELOP THE SCIENTIFIC STRATEGIC PLAN
20	AND THE LEADERSHIP IS GOING TO RESIDE WITHIN THE
21	INSTITUTE. BUT WHAT I INTERPRET THAT PARTICULAR
22	PIECE OF PROP 71 TO EXPLICITLY CREATE IS A PUBLIC
23	PROCESS FOR DOING SO IN THAT IT IS AN ICOC FUNCTION
24	THAT BRINGS IT UNDER BAGLEY-KEENE, AND THAT MAKES IT
25	A PUBLIC PROCESS. SO MUCH LIKE WHEN ZACH CONDUCTED

33

1	HIS PROCESS, HE EXERTED TREMENDOUS LEADERSHIP AND,
2	YOU KNOW, ULTIMATELY WENT BEHIND CLOSED DOORS TO
3	PULL ALL THE DIFFERENT PIECES TOGETHER, BUT THAT WAS
4	A VERY ROBUST PUBLIC PROCESS.
5	AND I THINK THAT THE INSTITUTE AND THE
6	ICOC BENEFITED FROM THAT PROCESS. AND I REALLY DO
7	THINK THAT THAT'S EXPLICIT IN PROP 71, THAT THAT
8	WOULD BE A PUBLIC PROCESS. SO I'M NOT TRYING
9	THERE'S NO WAY 29 MEMBERS OF US CAN PULL TOGETHER A
10	STRATEGIC PLAN. BUT THE PUBLIC ASPECT OF THAT WHICH
11	IS EXPLICIT IN PROP 71 SHOULD BE HONORED.
12	DR. POMEROY: OKAY. I'M ADDING THAT
13	COMMENT IN HERE.
14	MR. KLEIN: I'D LIKE TO COMMENT ON THAT,
15	JEFF. YOU KNOW, THE BOARD, WHEN ZACH WAS THERE,
16	VERY CLEARLY DEFINED THAT WE LOOK TO THE PRESIDENT
17	AND THE PRESIDENT'S SCIENTIFIC STRATEGIC VISION TO
18	LEAD US IN PUTTING TOGETHER THE PROCESS FOR THE
19	STRATEGIC PLAN AND THEN DRAWING TOGETHER THE
20	COMPONENTS OF THE STRATEGIC PLAN. SO WHILE IT WAS A
21	PUBLIC PROCESS, ZACH DESIGNED THAT PROCESS TO GET
22	OUTSIDE SCIENTIFIC INPUT, INTERNAL SCIENTIFIC INPUT,
23	BUT IT WAS VERY MUCH A BENEFIT WE BENEFITED FROM
24	THE VISION OF THE PRESIDENT IN THAT PROCESS AND THE
25	LEADERSHIP OF THE PRESIDENT BECAUSE THE PRESIDENT

34

1	WILL HAVE TO BELIEVE IN THE SCIENTIFIC PLAN TO
2	PASSIONATELY BE COMMITTED TO IMPLEMENTING IT.
3	AND IT IS VERY IMPORTANT, I THINK, THAT WE
4	WENT ALL THE WAY ACROSS SEVERAL CONTINENTS TO GET
5	SOMEONE WHO HAD LED THE REVOLUTION FOR IN VITRO
6	FERTILIZATION, SCIENTIFIC REVOLUTION OF TREMENDOUS
7	MAGNITUDE, WHO HAS GLOBAL CONTACTS AND KNOWLEDGE AND
8	EXPOSURE TO HELP LEAD IT TO A PROCESS THAT DOESN'T
9	JUST REPEAT THE GOOD RECORD OF THE NIH, BUT ONE THAT
10	CAN HAVE INNOVATIONS LIKE THE DISEASE TEAMS AND THE
11	SCALE OF THE DISEASE TEAM EFFORT.
12	SO WHILE I THINK IT'S VERY IMPORTANT, AND
13	I'D LIKE TO GET DR. TROUNSON'S INPUT THERE BECAUSE
14	WE'RE PARTNERS WITH THE PRESIDENT IN THIS PROCESS,
15	BUT IT'S HIS SCIENTIFIC LEADERSHIP THAT'S GOING TO
16	HELP INSPIRE THE STRATEGIC PLAN. SO I THINK IT'S
17	IMPORTANT TO HAVE, SHERRY, HIS COMMENTS.
18	CHAIRPERSON LANSING: I DEFINITELY WANT IT
19	AS SOON AS I'M DONE WITH THE SUBCOMMITTEE MEMBERS.
20	SO I JUST WANT TO SEE OF THERE ARE ANY OTHER
21	COMMENTS FROM THE SUBCOMMITTEE MEMBERS.
22	DR. POMEROY: SHERRY, I WANT TO JUST
23	CLARIFY FOR EVERYBODY ON THIS THAT THE PROPOSAL AND
24	RECOMMENDATION IS NOT TO RESTRICT THE PRESIDENT TO
25	DOING THE SCIENTIFIC COMPONENTS OF THE STRATEGIC
	35

-	
1	PLAN, BUT, IN FACT, THE PRESIDENT IS RESPONSIBLE FOR
2	ALL ASPECTS OF AND ALL STRATEGIES, SCIENTIFIC AND
3	OTHERWISE, OF CIRM, EXCEPT FOR THE EXTERNAL
4	FINANCING PLAN. SO I DON'T WANT ANYONE TO
5	MISINTERPRET THE PREVIOUS DISCUSSION TO THINK THAT
6	THE PRESIDENT IS ONLY RESPONSIBLE FOR THE SCIENTIFIC
7	STRATEGI ES.
8	CHAI RPERSON LANSI NG: THANK YOU, CLAI RE,
9	FOR THAT CLARIFICATION.
10	MR. SHEEHY: YOU KNOW, I JUST WANT TO
11	RESPOND TO BOB'S COMMENTS. I'M JUST REALLY TRYING
12	TO STAY WITHIN THE CONFINES OF THE LAW. AND, YOU
13	KNOW, I DO THINK THAT THERE'S AN EXPLICIT COMMITMENT
14	TO A PUBLIC PROCESS FOR THIS. AND I THINK WE'VE
15	SEEN THAT IT CAN WORK. AND THE DISEASE TEAMS IS A
16	GREAT EXAMPLE. I CAN POINT TO THE TWO MEETINGS
17	WHERE THE GENESIS OF THE DISEASE TEAMS CAME FROM AND
18	THE PUBLIC COMMENTS THAT WERE MADE AND THE PEOPLE
19	WHO PARTICIPATED. SO, YOU KNOW, I CERTAINLY
20	APPRECIATE THE SCIENTIFIC LEADERSHIP WE HAVE AT OUR
21	DISPOSAL, BUT WE DO HAVE AN OBLIGATION FOR
22	TRANSPARENCY WITH THE PUBLIC.
23	SO I DON'T THINK WE'RE FAR APART. I DON'T
24	THINK THERE'S A BIG DEBATE HERE, BUT I THINK WE
25	DON'T HAVE TO GET INTO THE WEEDS ON THIS.
	36

1	DR. POMEROY: JEFF, I THINK I CAN PUT SOME
2	WORDING OUT THAT INDICATES THAT OUR EXPECTATION IS
3	THAT THE PUBLIC, THE CIRM STAFF, AND THE ICOC SHOULD
4	ALL HAVE INPUT INTO THIS PROCESS.
5	MR. KLEIN: JEFF, I CERTAINLY COMPLETELY
6	ENDORSE AND EMBRACE THE PUBLIC PROCESS THAT ZACH PUT
7	TOGETHER UNDER HIS LEADERSHIP. WHAT'S IMPORTANT
8	HERE, THOUGH, IS THAT HE MADE SCIENTIFIC DECISIONS
9	AT THAT TIME AT THAT SCIENTIFIC PLAN. THE PROVISION
10	FOR GMP, GOOD MANUFACTURING PRACTICES, FOR
11	DEVELOPMENT OF THERAPEUTIC GRADE PRODUCTION FOR
12	THERAPIES IS NOT A NECESSARY COMPONENT, BUT IN THIS
13	PHASE THE SCIENTIFIC JUDGMENT MAY BE DIFFERENT.
14	S0
15	CHAIRPERSON LANSING: I THINK WHAT YOU ARE
16	SAYING, BOB, I THINK WHAT JEFF AND EVERYONE IS
17	AGREEING IS THAT WE HAVE A PLAN, BUT WE ALSO HAVE TO
18	RECOGNIZE THAT THE PLAN HAS TO EVOLVE, DO YOU KNOW,
19	THAT IT'S CONSTANTLY CHANGING AS THE SCIENCE
20	CHANGES.
21	MR. KLEIN: THE SCIENTIFIC LEADERSHIP OF
22	THE PRESIDENT IS CRITICAL IN LEADING US IN THAT WAY.
23	CHAIRPERSON LANSING: I THINK WE ARE ALL
24	IN AGREEMENT ON THAT.
25	MR. ROTH: JUST A COUPLE OF THOUGHTS ON
	37

1	HOW THIS DOCUMENT SHOULD REALLY FOLLOW PROP 71 IN
2	TERMS OF THE DUTIES AND RESPONSIBILITIES OF WHO IS
3	IN CHARGE, AND WHETHER THERE'S INFORMAL AGREEMENTS
4	ABOUT LEADERSHIP ON ONE ITEM OR ANOTHER CAN HAPPEN.
5	WE DON'T HAVE TO PUT IT INTO THE DOCUMENT EVERY TIME
6	WE AGREE TO SOMETHING LIKE THAT.
7	SO IN MY READING OF THIS, AND I THINK WHAT
8	CLAIRE TRIED TO EXPRESS, IS A SIMPLIFICATION SORT OF
9	BACK TO WHERE THE ULTIMATE RESPONSIBILITY LIES AND
10	THEN FIGURE OUT IF THEY WANT TO DELEGATE THOSE
11	RESPONSIBILITIES, THAT CERTAINLY WE SHOULD BE AWARE
12	OF THOSE, BUT WE DON'T HAVE TO CHANGE THIS POLICY
13	EVERY TIME.
14	CHAIRPERSON LANSING: RIGHT. I AGREE WITH
15	THAT. ANY MORE SUBCOMMITTEE BEFORE I GO TO STAFF?
16	DR. STEWARD: ONE OF THE THINGS THAT I
17	THINK THAT WE SHOULD THINK ABOUT, ALTHOUGH I'M NOT
18	SURE IT ACTUALLY NEEDS TO GO EXPLICITLY INTO THE
19	DOCUMENT, IS A LITTLE BIT OF THE DETAILS IN TERMS OF
20	THE ACTUAL PROCEDURE THROUGH WHICH THE STRATEGIC
21	PLAN WOULD BE DEVELOPED. BY THAT I MEAN EXACTLY WHO
22	WRITES THE DRAFT AND WHEN BECAUSE I THINK THAT WE
23	NEED TO MAKE IT CLEAR OBVIOUSLY THAT PUBLIC INPUT IS
24	IMPORTANT AND BOARD INPUT IS IMPORTANT AND ALL
25	STAKEHOLDER INPUT IS IMPORTANT, BUT SOMETIMES IT'S

38

1	ACTUALLY EASIER TO HAVE A WORKING DRAFT AS YOU GO
2	ALONG.
3	AND I WOULD JUST LIKE TO TRY TO MAKE IT
4	SOMETHING THAT WOULD BE CLEAR UP FRONT SO THAT, FOR
5	EXAMPLE, STAFF DIDN'T WASTE A LOT OF TIME PREPARING
6	A DOCUMENT THAT WE WOULD THEN NOT CONSIDER AT ALL
7	AND GO BACK AND LISTEN TO PUBLIC COMMENT OR VICE
8	VERSA. JUST MAKE THE INSTRUCTIONS VERY CLEAR.
9	DR. POMEROY: OS, DO YOU AGREE THAT THAT
10	VERY APPROPRIATELY COULD BE OUTLINED IN THE SETTING
11	OF THE ANNUAL OBJECTIVES AND DELIVERABLES WITHOUT
12	HAVING TO PUT IT IN THE INTERNAL GOVERNANCE POLICY?
13	DR. STEWARD: ABSOLUTELY. I DON'T THINK
14	THE RIGHT PLACE IS THE INTERNAL GOVERNANCE POLICY.
15	I JUST THINK IT SHOULD BE THERE SOMEWHERE SO IT'S
16	CLEAR UP FRONT.
17	CHAI RPERSON LANSI NG: THANK YOU. GOOD
18	POINTS, DUANE. ANY OTHER SUBCOMMITTEE? NOW I'D
19	LIKE TO TURN TO STAFF. ALAN, I WELCOME YOUR
20	COMMENTS.
21	DR. TROUNSON: THANK YOU, SHERRY. I THI NK
22	IT'S CLARITY THAT I'M PARTICULARLY SEEKING. SO I
23	THINK THIS DISCUSSION HAS HELPED IN SOME OF THAT, TO
24	BE HONEST. YOU KNOW, IT WASN'T ALL THAT CLEAR TO ME
25	FROM THE RANGE OF COMMENTS THAT WERE AT THE LAST
	39

1	BOARD MEETING. IT WAS A REAL DIVERSITY OF COMMENTS
2	HERE. SO I THINK IT REALLY DOES HELP IF WE HAVE
3	CLARI TY.
4	ONE OF THE IMPORTANT THINGS I THINK YOU
5	ALL RECOGNIZE ANYWAY, THAT THERE IS A TREMENDOUS
6	CHANGE GOING ON AND CHANGE WHICH IS SHOOTING THE
7	DIRECTION OF THE SCIENCE AND THE TECHNOLOGY IN
8	DIRECTIONS, I THINK, LET ALONE PREDICT TWO MONTHS
9	AGO OR THREE MONTHS AGO. SO THIS IS HAPPENING IN
10	REAL TIME. AND WHAT WE'RE TRYING TO DO IS
11	ACCOMMODATE THE CHANGES TO REFLECT AN APPROPRIATE
12	RESPONSE IN THE ORIGINAL PLAN. WE'RE NOT REALLY
13	TRYING TO CHANGE THE ORIGINAL PLAN. IN FACT, THE
14	GOALS WERE EXACTLY THE SAME. WHAT WE'RE TRYING TO
15	DO IS REPOSITION OURSELVES APPROPRIATELY TO
16	ACCOMMODATE THE CHANGES, THE TREMENDOUS CHANGES THAT
17	ARE GOING ON. AND THAT INCLUDES NOW POLITICAL
18	CHANGE, WHICH IS AFFECTING GOVERNMENT, BUT ALSO
19	AFFECTING THE ATTITUDE, FOR EXAMPLE, OF THE
20	PHARMACEUTICAL INDUSTRY DRAMATICALLY.
21	SO WE'RE IN A VERY DIFFERENT POSITION, I'D
22	SUGGEST, THAN WE WERE BACK IN 2006. I WELCOME THE
23	IDEA OF HAVING MORE PUBLIC INPUT. WHAT I DON'T WANT
24	TO DO IS DRAG IT OUT FOR A VERY LONG TIME BECAUSE I
25	THINK WE'LL NEED TO REDO IT AGAIN IN PERHAPS TWO
	10

40

1	YEARS' TIME. BUT WE WOULD LIKE TO HAVE A PUBLIC
2	MEETING, PARTICULARLY WITH INDUSTRY BECAUSE IT'S
3	CHANGING SO QUICKLY ON US. AND THERE ARE A VERY
4	LARGE NUMBER OF INPUTS THAT WE COULD GET, AND I
5	THINK WE OUGHT TO SEEK.

I THINK PUBLICLY IN OTHER AREAS I THINK 6 7 THINGS ARE CHANGING. THERE ARE TREATMENTS OUT THERE 8 THAT ARE BEING USED IN MANY WAYS. I DON'T KNOW HOW EFFECTIVELY, BUT THEY'VE GOT CLINICAL TRIALS ON 9 10 THINGS THAT WE WOULD NEVER HAVE THOUGHT ABOUT TWO YEARS AGO. AND DO WE WANT TO BE POSITIONED MORE 11 CLOSELY WITH THOSE, OR DO WE WANT TO SORT OF 12 13 MAINTAIN, LET ME JUST SAY, PURITY OF STEM CELL TYPE? I ACTUALLY THINK WE NEED A MIXTURE. AND I THINK 14 WHAT WE NEED IS TO ENSURE THAT THE GOAL ENDS UP WITH 15 16 TREATMENTS IN THE CLINIC.

17 SO THE RECOMPOSITION OR THE REFURBISHMENT OF THE PLAN IS REALLY MEANT TO TRY AND ACCOMMODATE 18 19 THESE CHANGES. AND SO IT WOULD BE HELPFUL FOR US TO EXPLAIN THAT, AND WE'RE TRYING, BECAUSE OF A VERY, 20 21 VERY GOOD STAFF HERE, TRYING TO GET SOME DUMPING DOWN OF WHAT THEY THOUGHT WERE THE MAJOR THINGS THAT 22 WERE HAPPENING AND MAYBE THE KIND OF RESPONSES THAT 23 24 WE COULD MAKE, BUT WE OUGHT TO TURN THAT INTO 25 SOMETHING THAT THEN CAN BE REFLECTED IN THE PUBLIC,

41

1	SO WE HAVE NO PROBLEM WITH THAT.
2	I THINK IF WE GET A CLARITY OF PROCESS,
3	AND I THINK YOU NEED TO UTILIZE THE TREMENDOUS
4	SCIENCE AND CAPACITY THAT'S INTERNAL, BUT ALSO, YOU
5	KNOW, GET SOME OF THE FLAVOR OF VIEWS THAT ARE OUT
6	THERE. FOR EXAMPLE, IN THE CANCER WORLD, THERE'S A
7	HECK OF A LOT OF DEBATE ABOUT CANCER STEM CELLS.
8	THOSE ARE GREAT OPPORTUNITIES, BUT THERE'S GREAT
9	DEBATE, SO WE NEED TO BE IN A FLEXIBLE POSITION, BUT
10	IN AN OPPORTUNE WAY OF BEING ABLE TO PICK UP MAJOR
11	TREATMENTS. CANCER STILL IS AFFECTING MORE PEOPLE
12	THAN ANYTHING ELSE, I THINK.
13	SO IT'S REALLY US BEING THE VEHICLE OF
14	WHAT YOU NEED TO DELIVER THE MISSION BECAUSE THE
15	MISSION I DON'T THINK EVER, EVER CHANGES. IT'S A
16	GOLD LEAF TO US. WE JUST NEED TO REFORMAT THE WAY
17	WE DO THINGS TO BE BETTER PREPARED TO DELIVER ON
18	THAT MISSION BECAUSE IF IT'S TREATMENTS IN THE NEXT
19	FIVE TO SIX YEARS THAT WILL HAVE AN IMPACT ON
20	PATIENTS, THAT'S WHAT WE ALL WANT. SO WE'RE
21	PREPARED TO BE RESPONSIVE. AND WE JUST SEEK I
22	THINK WE'RE JUST SEEKING SOME CLARITY ON HOW TO GO
23	ABOUT IT.
24	CHAI RPERSON LANSI NG: THANK YOU. I JUST
25	WANT THAT WAS VERY, VERY ARTICULATELY PUT AND
	42

1	THANK YOU. IS THERE ANY MORE INPUT FROM THE STAFF?
2	DR. FONTANA: I HAVE A COMMENT TOO ON
3	THAT. I THINK IT ALSO BRINGS BACK JEFF'S POINT AND
4	GOES BACK TO A COMMENT THAT I MADE AT THE LAST ICOC
5	MEETING WHERE, ALAN, I AM IN AGREEMENT WITH WHAT YOU
6	ARE SAYING, BUT WOULD LIKE TO INCLUDE THE VERY
7	BENEFICIAL INPUT THAT THE PUBLIC GIVES. WHEN I SAY
8	PUBLIC, I MEAN INCLUDING INDUSTRY, ADVOCACY GROUPS,
9	AND THE SCIENTISTS.
10	AS A SUGGESTION PERHAPS THIS COULD OCCUR
11	AT THE ANNUAL CIRM GRANTEES' MEETING MAYBE AT THE
12	END OF I KNOW THEY'RE LONG DAYS, BUT A DAY WHERE
13	THE SCIENTISTS ARE THERE, BUT ALSO INVITE THE PUBLIC
14	AND INDUSTRY AT THAT TIME TO GIVE WHAT WOULD BE AN
15	ANNUAL PERFORMANCE EVALUATION. BECAUSE I FOUND
16	THOSE CONVERSATIONS TO BE VERY HELPFUL AND
17	INSIGHTFUL, AND MAYBE THAT WOULD BE A FORMAT BY
18	WHICH WE COULD GET SOME HELPFUL FEEDBACK WITHOUT IT
19	BEING A CUMBERSOME, LONG, DRAWN-OUT ADDITIONAL
20	MEETING.
21	DR. TROUNSON: SURE, JEANNIE. THIS YEAR
22	COMING UP, THOUGH, THE ISSCR MEETING IS IN SPAIN IN
23	BARCELONA. SO I THINK WE'RE NOT I'M NOT QUITE
24	SURE. WE'RE NOT EXPECTING TO HAVE A MEETING UNTIL
25	MARCH THE FOLLOWING YEAR.

43

1	DR. FONTANA: WE'RE NOT HAVING ANNUAL
2	GRANTEE MEETINGS?
3	DR. TROUNSON: MARIE IS MAKING COMMENTS TO
4	THE SIDE THAT IT'S MORE LIKE ABOUT EVERY 18 MONTHS.
5	WE JUST NEED TO MAKE SURE THAT WE DON'T DUPLICATE
6	TOO MUCH OF WHAT HAPPENS AT THE ISSCR. SO WHILE I
7	AGREE THAT THAT IS A FORUM FOR DOING THAT, IT MIGHT
8	NOT SUIT THE TIMEFRAMES THAT WE'RE CURRENTLY IN TO
9	WAIT THAT LONG.
10	MR. KLEIN: BUT FOR JEANNIE'S POINT, IN
11	2010 WE HAVE THE TREMENDOUS CROSS-FERTILIZATION OF
12	HAVING THE INTERNATIONAL MEETING IN SAN FRANCISCO.
13	SO ALL THE CIRM SCHOLARS AND EVERYONE CAN HAVE A
14	HUGE BENEFIT ALONG WITH OUR SCIENTISTS AND PHYSICIAN
15	SCIENTISTS OF THAT CROSS-FERTILIZATION FROM AROUND
16	THE WORLD.
17	CHAI RPERSON LANSI NG: CLAI RE, SO I HAVE
18	THIS UNAVOIDABLE CONFLICT. SO I'M GOING TO ASK YOU
19	TO CONTINUE THE MEETING IN MY REGRETTABLE ABSENCE.
20	I'M VERY SORRY ABOUT THIS SCHEDULING CONFLICT. BUT
21	IF YOU CAN ASK FOR COMMENTS FROM THE PUBLIC AND MORE
22	COMMENTS FROM STAFF, WHATEVER, AND THEN I'LL LET YOU
23	LEAD THE CLOSED SESSION. AND I'D ASK MY ASSOCIATE
24	DOUG TO SIT IN FOR THE PUBLIC PART, SO HE CAN TELL
25	ME WHAT HAPPENED. AGAIN, THANK YOU ALL.

44

BARRISTERS' REPORTING SERVICE 1 DR. POMEROY: THANK YOU, SHERRY. ARE 2 THERE ADDITIONAL COMMENTS ABOUT THE INTERNAL GOVERNANCE POLICY FIRST FROM THE COMMITTEE MEMBERS? 3 HEARING NONE, FROM THE PUBLIC. 4 5 MS. KING: WE HAVE ONE HERE IN SAN FRANCI SCO. 6 7 MR. REED: THIS IS DON REED. I THINK IT'S 8 CRUCIAL THAT THE WIDERANGING INCLUSIVE NATURE WHICH 9 HAS GIVEN US SUCCESS NOW BE CONTINUED. THE 10 PRESIDENT WILL HAVE ENORMOUS INFLUENCE OVER THE DRAFT. HE WILL PROBABLY BE DOING THE BULK OF THE 11 WRITING, AS ZACH HALL, FROM MY IMPRESSION, DID. BUT 12 13 I THINK THAT THE INCLUSION IS VITAL. IN THE ARMY THEY USED TO TEACH US IF YOU 14 DON'T KNOW WHAT TIME IT IS, ASK EVERYBODY, ADD UP 15 16 THE NUMBERS, AND DIVIDE THEM BY THE NUMBER OF 17 PEOPLE, AND YOU GET IT VERY ACCURATE. I THINK THAT'S A CRUCIAL THING. 18 19 I REMEMBER ONE PARTICULAR INCIDENT. THERE WAS A BIG CONFLICT BETWEEN THE CITIZENS, THE 20 21 ADVOCATES, AND THE SCIENTISTS, FROM MY VIEWPOINT, MY 22 PERSPECTIVE, WHAT WAS ACHIEVABLE AND WHAT SHOULD BE 23 TRIED FOR. AND WE FINALLY AGREED THAT THERE WOULD 24 BE TWO GOALS, AN IMMEDIATE AND AN ASPIRATIONAL. 25 NOW, ONLY THAT INTERPLAY BETWEEN THE TWO

1	FORCES BROUGHT ABOUT THAT EMINENTLY SENSIBLE
2	COMPROMISE. SO I STRONGLY ENDORSE THE IDEA OF
3	TAKING A LITTLE EXTRA TIME AND MAKING SURE THE
4	PUBLIC IS THOROUGHLY ENGAGED IN THIS.
5	DR. POMEROY: THANK YOU, DON. COMES WITH
6	MULTIPLE PERSPECTIVES. OTHER PUBLIC COMMENT?
7	MR. SIMPSON: JOHN SIMPSON, CONSUMER
8	WATCHDOG. TWO THINGS. I JUST WANTED TO REITERATE
9	THE IMPORTANCE OF MAKING SURE THAT THERE IS MAXIMUM
10	INPUT FOR THE STRATEGIC PLAN, AND HOPE THAT WE'LL
11	GET SOME OF THAT ON THE PLAN THAT'S OUT THERE
12	PENDING RIGHT NOW. I DON'T KNOW WHAT THE MECHANISMS
13	FOR THAT WILL BE.
14	THE OTHER ISSUE IS THAT WHILE THE
15	CONVERSATION, I THOUGHT, WAS VERY VALUABLE, AS FAR
16	AS THE PROPOSED CHANGES IN THE BYLAWS, IT MAY JUST
17	BE A COMMENT ON MY ABILITY TO FOLLOW SUCH A
18	CONVERSATION. IT WAS EXTREMELY DIFFICULT TO DO THAT
19	WITHOUT SOME SORT OF WRITTEN DOCUMENT, AND IT SEEMED
20	TO ME THAT ONE EXISTED AND THAT YOU WERE READING
21	FROM IT. SO I WOULD HOPE THAT AS SOON AS POSSIBLE,
22	AS THIS CONVERSATION GOES FURTHER, THAT DOCUMENT
23	WILL BE MADE PUBLIC. THANK YOU.
24	DR. POMEROY: AND I DO WANT TO JUST ASSURE
25	EVERYBODY THAT THE PLAN IS TO INCORPORATE ALL OF
	46
	77

1	TODAY'S COMMENTS AND PUT OUT A DOCUMENT IN ADVANCE
2	FOR THE NEXT GOVERNANCE COMMITTEE.
3	MR. SIMPSON: THANK YOU.
4	DR. POMEROY: OTHER PUBLIC COMMENTS?
5	OKAY. IT'S BEEN VERY HELPFUL FOR THAT.
6	THERE IS ONE OTHER PART OF THE INTERNAL
7	GOVERNANCE POLICY WHICH WE WANTED TO GET INPUT ON.
8	THAT IS THE PART ABOUT THE ORGANIZATION OF THE
9	OFFICE OF THE CHAIR. FOR THOSE OF YOU WHO HAVE LOTS
10	OF EXTRA TIME, IF YOU WENT BACK AND READ THE MARCH
11	2007 VERSION OF THE INTERNAL GOVERNANCE POLICY, IT
12	CALLED FOR LIMITING THE OFFICE OF THE CHAIR TO NO
13	MORE THAN THREE EMPLOYEES TO SUPPORT THE CHAIR AND
14	ONE EMPLOYEE TO SUPPORT THE VICE CHAIR.
15	MR. KLEIN: WHERE WAS THIS?
16	DR. POMEROY: THIS IS IN THE MARCH 2007
17	INTERNAL GOVERNANCE POLICY, WHICH WAS THEN MODIFIED
18	IN DECEMBER OF '07 TO SIX PLUS TWO. AND I THINK
19	THAT SOME OF THE MEMBERS WERE NOT COMPLETELY AWARE
20	OF THE CHANGE BETWEEN THE MARCH AND THE DECEMBER '07
21	INTERNAL GOVERNANCE POLICY IN THIS SECTION. AND WE
22	WANTED TO OPEN THIS UP FOR INPUT AND DISCUSSION.
23	MR. KLEIN: THIS IS BOB KLEIN. CERTAINLY
24	WITH ME CUTTING BACK MY TIME TO HALF, GIVEN WHAT I
25	THINK THE OBJECTIVES ARE GOING TO BE OVER THE NEXT
	47

47

1	YEAR, THEY'RE GOING TO BE HIGHLY STRESSED. BUT I
2	THINK IT'S BEST IF YOU TAKE A LOOK AT THE OBJECTIVES
3	IN DETERMINING THE MANPOWER THAT'S NECESSARY. AND
4	MAYBE I CAN EVEN DRAFT A COUPLE OF BOARD MEMBERS
5	FULL TIME TO HELP BECAUSE I THINK THE OBJECTIVES IN
6	THE NEXT YEAR, GIVEN THE STATE'S CHALLENGES, ARE
7	GOING TO BE FAIRLY DAUNTING.
8	DR. POMEROY: AND, BOB, I WOULD AGREE THAT
9	THE CHAIR AND VICE CHAIR SHOULD BE SUPPORTED BY THE
10	FULL RANGE OF THE ICOC AND THE FULL RANGE OF ALL THE
11	CIRM STAFF. AND THAT IS ALSO MENTIONED AS AN
12	APPROPRIATE WAY TO GO IN THE INTERNAL GOVERNANCE
13	POLI CY.
14	ARE THERE OTHER COMMITTEE MEMBER COMMENTS
15	ABOUT THIS PART OF THE INTERNAL GOVERNANCE POLICY?
16	MR. ROTH: ARE THERE OTHER DIFFERENCES
17	BETWEEN THOSE TWO VERSIONS?
18	DR. POMEROY: THE ONLY THING IS THAT IT
19	SPECIFICALLY DELINEATES THE INDIVIDUALS IN THE
20	OFFICE OF THE CHAIR TO INCLUDE THE DIRECTOR OF
21	FINANCE, LEGAL, AND GOVERNMENTAL AFFAIRS, THE DEPUTY
22	TO THE CHAIR FOR FINANCE POLICY AND OUTREACH, AND
23	THE DIRECTOR OF GOVERNMENTAL AFFAIRS AS ALL BEING IN
24	THE OFFICE OF THE CHAIR. THOSE WERE NOT SPECIFIED
25	IN THE PREVIOUS VERSION, WASN'T SPECIFIED WHO THE

48

1	EMPLOYEES WOULD BE. OTHERWISE, IN MY REVIEW, THERE
2	ARE NO SIGNIFICANT OTHER DIFFERENCES.
3	MR. ROTH: SO MY INPUT WOULD BE THAT IT'S
4	PROBABLY TIME TO REVISIT THIS, ESPECIALLY GIVEN
5	WHAT'S GOING ON. BOB MAKES SOME IMPORTANT POINTS
6	ABOUT SOME OF THE CHALLENGES. ON THE OTHER HAND,
7	THESE ARE TOUGH TIMES. AND KEEPING THE HEAD COUNT,
8	ESPECIALLY A HEAD COUNT NOT DIRECTLY INVOLVED IN THE
9	GRANT PROCESS, IS PROBABLY SOMETHING WE HAVE TO BE
10	VERY JUDICIOUS ABOUT.
11	DR. POMEROY: OF COURSE, PROPOSITION 71
12	DOES LIMIT THE TOTAL NUMBER OF EMPLOYEES.
13	MR. ROTH: CORRECT. I JUST THINK IT'S
14	PROBABLY TIME TO TAKE OUT A CLEAN SHEET OF PAPER AND
15	ASK THE QUESTION ABOUT WHAT WE NEED. AND I KNOW BOB
16	HAS SOME THOUGHTS ON THAT. AND I'M SURE ALAN DOES
17	AND OTHERS. BUT I WOULD CERTAINLY HOPE, AS PART OF
18	THIS PROCESS, THAT WE REVISIT THAT.
19	MR. KLEIN: I WOULD CALL TO YOUR ATTENTION
20	THAT IN TERMS OF GOVERNMENTAL AFFAIRS AND THE
21	DIRECTOR OF FINANCE FOR EXTERNAL FINANCE, WE'RE IN
22	THE PROCESS OF HIRING THOSE PEOPLE RIGHT NOW AS WELL
23	AS THE ASSISTANTS. AND WE NEED TO DO THAT IF WE
24	HAVE ANY HOPE OF AVOIDING A MAJOR FUNDING GAP FOR
25	THIS AGENCY. IN FACT, IF WE HAD HAD A RUNNING START
	40

49

1	MAYBE 90 DAYS AGO, IT WOULD HAVE BEEN CLEAR THAT THE
2	LEGISLATURE AND THE GOVERNOR WOULD COME TO THE
3	IMPASSE THEY HAVE. BUT PARTICULARLY GIVEN THE
4	CURRENT PROPOSALS FOR SOLVING THAT IMPASSE, IT WOULD
5	APPEAR TO HAVE A MAJOR SHORTFALL. AND 2009, 2010
6	ARE NOW PROJECTED TO BE MUCH MORE SEVERE THAN THEY
7	WERE EVEN 90 DAYS AGO.
8	WE'RE GOING TO HAVE TO LOOK AT THE
9	POTENTIAL OF A PRIVATE PLACEMENT BOND ISSUE OF 250
10	TO \$300 MILLION TO FUND THIS AGENCY. I WOULD
11	SUGGEST THAT BOTH POLITICALLY AND ETHICALLY WE DO
12	NOT WANT TO BE IN A POSITION WHERE THE STATE CAN
13	ONLY ISSUE TEN BILLION AND NEEDS 15 BILLION OF BONDS
14	WHERE WE'RE HAVING TO TAKE BOND FUNDS THAT WOULD
15	OTHERWISE GO TO TEACHERS OR THE DISABLED.
16	WE NEED TO THINK ABOUT THE BAN MODEL AND
17	REALIZE THAT THE LEADERSHIP THAT WAS IN THE
18	TREASURER'S OFFICE THAT REALLY HELPED CONSTRUCTIVELY
19	AS A TEAM DO THE BOND ANTICIPATION NOTE MODEL,
20	THEY'VE LEFT. THE TREASURER IS GONE, DEPUTY
21	TREASURER IS GONE, THE SENIOR CIVIL SERVANT IS GONE.
22	AND THE PEOPLE THAT ARE LEFT REALLY WERE NOT AT ALL
23	KEY, AND SOME MIGHT ARGUE HAD SOME MAJOR CONFLICTS
24	WITH OUR LEGAL TEAM WHICH THE TREASURER HAD TO
25	SOLVE. SO IT IS IMPORTANT TO REALIZE WE HAVE GOT A

50

1	MAJOR JOB TO DO TO WORK WITH THE TREASURER'S OFFICE
2	HERE.
3	AND IF WE'RE GOING TO PRIVATELY PLACE \$250
4	MILLION WORTH OF BONDS, WE'VE GOT AN ENORMOUS
5	CHALLENGE IN THIS FINANCIAL ENVIRONMENT, NOT ONE
6	THAT IS SOMETHING ANYONE WOULD EVER WANT TO DO, BUT
7	WE'RE GOING TO HAVE TO REALIZE WE'VE GOT FUNDING
8	THROUGH JUNE. TO GET PAST JUNE, YOU' RE GOI NG TO
9	HAVE TO BE REALLY FULLY STAFFED AND ENGAGED.
10	THE TREASURER'S OFFICE HAS GOT PHENOMENAL
11	CHALLENGES. THEY CAN'T AFFORD TO DEDICATE STAFF TO
12	GO OUT AND DO A PRIVATE PLACEMENT.
13	DR. POMEROY: THANK YOU FOR THAT INPUT,
14	BOB. ARE THERE OTHER COMMITTEE MEMBER COMMENTS?
15	ARE THERE PUBLIC COMMENT? PUBLIC COMMENT IN SAN
16	FRANCI SCO?
17	MS. KING: DOESN'T LOOK LIKE WE HAVE ANY
18	PUBLIC OR STAFF COMMENTS AT THIS TIME.
19	DR. POMEROY: IN L.A.?
20	MR. SIMPSON: JOHN SIMPSON, CONSUMER
21	WATCHDOG. I THINK THAT THIS IS A VERY DIFFICULT
22	AREA THAT'S GOING TO REQUIRE VERY CLOSE EXAMINATION.
23	I THINK THAT DUANE ROTH'S SUGGESTION, IT'S TIME FOR
24	A CLEAN SLATE AND SERIOUSLY THINKING IS IN ORDER,
25	BUT I THINK THAT BOB KLEIN LAID OUT SOME VERY
	F 1

-	
1	SIGNIFICANT CHALLENGES. SO I HOPE THIS IS
2	THOROUGHLY DI SCUSSED AND THOROUGHLY THOUGHT THROUGH
3	IN A COMPLETELY PUBLIC AND TRANSPARENT WAY.
4	DR. POMEROY: THANK YOU. IF THERE ARE NO
5	OTHER COMMENTS ON THE INTERNAL GOVERNANCE POLICY, I
6	THINK WHAT WE WILL DO IS GO BACK AND INCORPORATE AS
7	MANY OF THESE COMMENTS AS POSSIBLE AND ISSUE A
8	WRITTEN VERSION FOR PEOPLE TO STUDY AND DISCUSS AT
9	OUR NEXT GOVERNANCE SUBCOMMITTEE.
10	ARE THERE ANY OTHER COMMENTS BEFORE WE GO
11	FROM THE GO INTO CLOSED SESSION FROM THE
12	COMMITTEE MEMBERS? IF NOT, WE WILL GO INTO CLOSED
13	SESSION NOW. JAMES, CAN YOU STATE THE CODE SECTION
14	THAT ALLOWS US TO DO THIS?
15	MR. HARRISON: YES, INDEED. WE'LL BE
16	CONVENING A CLOSED SESSION PURSUANT TO GOVERNMENT
17	CODE 11126(A) AND HEALTH AND SAFETY CODE
18	125290.30(D)(3)(D).
19	MR. ROTH: JAMES, BEFORE YOU DO THAT, I
20	WASN'T PLANNING TO GO INTO THIS SESSION FOR OBVIOUS
21	REASONS. SHOULD I CALL IN? THERE'S NO VOTING
22	THAT'S GOING TO TAKE PLACE IN CLOSED SECTION?
23	MR. HARRISON: THAT'S CORRECT, DUANE.
24	WE'LL LET YOU KNOW WHEN WE RETURN TO OPEN SESSION.
25	MR. ROTH: I PROBABLY WILL NOT CALL IN
	F 2
	52

BARRISTERS' REPORTING SERVICE UNLESS THERE'S A NEED FOR THAT. I'VE GOT A MEETING 1 2 THAT STARTS IN TEN MINUTES. MR. HARRISON: THAT'S FINE. I SUSPECT 3 WE'LL JUST RETURN TO OPEN SESSION AND ANNOUNCE THAT 4 THERE'S NO ACTION TO REPORT AND THAT WE'RE 5 ADJOURNI NG. 6 7 MR. SIMPSON: IF I MAY, WHEN WOULD YOU 8 EXPECT THAT THAT WRITTEN VERSION OF THE BYLAWS 9 CHANGES MIGHT BE AVAILABLE? AND DO YOU HAVE AN IDEA 10 WHEN THE NEXT GOVERNANCE COMMITTEE MEETING MIGHT TAKE PLACE? 11 DR. POMEROY: WE DON'T YET HAVE THE NEXT 12 13 GOVERNANCE COMMITTEE SCHEDULED. I BELIEVE THAT'S CORRECT, RIGHT, MELISSA? 14 MS. KING: YES. THAT IS CORRECT. AND 15 16 ALSO I WAS TRYING TO MAKE SURE THAT MR. SIMPSON 17 REALIZES THAT THE DOCUMENT HE'S REFERRING TO IS ACTUALLY THE INTERNAL GOVERNANCE POLICY. 18 19 DR. POMEROY: THANK YOU FOR THAT CLARIFICATION. WE WILL BEGIN TO WORK ON THAT RIGHT 20 21 AWAY, AND WE WILL MAKE SURE THAT WE HAVE IT OUT WITHIN AT LEAST TEN DAYS IN ADVANCE SO THAT PEOPLE 22 23 HAVE A CHANCE TO STUDY IT. 24 MR. SIMPSON: THANK YOU VERY MUCH. 25 DR. POMEROY: WITH THAT, WE'LL NOW GO INTO 53

CLOSED SESSION. AND IF EVERYONE CAN HANG UP NOW AND
DIAL IN, THE COMMITTEE MEMBERS DIAL INTO THE CLOSED
SESSION, WE'LL REPORT OUT IN OPEN SESSION
AFTERWARDS.
(THE COMMITTEE THEN WENT INTO CLOSED
SESSION, NOT REPORTED NOR HEREIN TRANSCRIBED. THE
COMMITTEE THEN MET IN OPEN SESSION AS FOLLOWS:)
DR. POMEROY: THANK YOU VERY MUCH.
WELCOME BACK TO THE OPEN SESSION. I WANT TO
OFFICIALLY REPORT THAT NO ACTION WAS TAKEN IN THE
CLOSED SESSION DESPITE SPIRITED CONVERSATIONS.
ARE THERE ANY ADDITIONAL COMMENTS FROM THE
COMMITTEE MEMBERS AT ANY OF THE LOCATIONS?
MR. KLEIN: I WOULD LIKE TO THANK ALL OF
THE COMMITTEE MEMBERS FOR THEIR PASSIONATE
COMMITMENT, AND WISH YOU ALL HAPPY HOLIDAYS AND
MERRY CHRISTMAS AS APPROPRIATE. AND TELL YOU THAT
THERE'S BEEN A MAGNIFICENT CONTRIBUTION FROM THE
MEMBERS OF THIS COMMITTEE OVER THE LAST FOUR PLUS
YEARS, ALMOST FIVE YEARS. AND IT IS WONDERFUL TO
HAVE PEOPLE OF DEEP PASSION COMMITTED, AND THE
DIVERSITY OF OPINION ENRICHES US ALL.
DR. POMEROY: BOB, VERY WELL SAID. AND WE
THANK YOU FOR YOUR LEADERSHIP AND MAKING ALL OF THAT
POSSI BLE.

	BARRISTERS' REPORTING SERVICE
1	DR. FONTANA: THANK CLAIRE FOR HOSTING OR
2	CHAI RI NG THI S.
3	DR. POMEROY: ARE THERE ANY FURTHER PUBLIC
4	COMMENT? ANY PUBLIC COMMENT?
5	MR. SHEEHY: NOT IN SAN FRANCISCO.
6	DR. POMEROY: OKAY. HAPPY HOLIDAYS,
7	EVERYBODY. THE MEETING STANDS ADJOURNED.
8	(THE MEETING WAS THEN ADJOURNED AT
9	05:31 P.M.)
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
	55
	1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

REPORTER' S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE GOVERNANCE SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING ON DECEMBER 22, 2008, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

IN

BETH C. DRAIN, CSR 7152 BARRISTER'S REPORTING SERVICE 1072 BRISTOL STREET SUITE 100 COSTA MESA, CALIFORNIA (714) 444-4100